Cell Host-Microbe Interactions: Turning Pathogen

Mechanisms Into Cell's Advantages by Avanzi, Simone
Alma Mater Studiorum – Università di Bologna
DOTTORATO DI RICERCA IN
Scienze Biomediche: Progetto n. 1 "Biotecnologie Mediche"
Ciclo XXV
Settore Concorsuale di afferenza:        06A3
    Settore Scientifico disciplinare:      MED07
TITOLO TESI
“Cell Host-Microbe Interactions: Turning Pathogen 
Mechanisms Into Cell's Advantages”
Presentata da: Dott. Simone Avanzi
Coordinatore Dottorato     Relatore
Prof. Lucio Cocco       Prof.ssa Marialuisa Zerbini
Esame finale anno 2013
INDEX           2
Introduction           3
Abstract           5
Chapter I - Chlamydiaceae Moves to the Nucleus: Whole Proteome Analysis Scanning for  
         Nuclear Localization Signals       6
Chapter II - Susceptibility of Human Placenta Derived Mesenchimal Stromal/Stem Cells to 
___________Human Herpesviruses Infection      23
Chapter III - Turning the HIV integrase into a dis-integrase: tailoring a viral enzyme to promote 
          the disruption of its natural target      50
2
INTRODUCTION
Describing host-pathogen interactions in few pages is far to be exhaustive and it  is not my intent. With 
this brief introductory part  I would like to take into account  several well-known host-pathogen interac-
tions. My hope is that this would help the reader to understand how sophisticate are the strategies adopted 
from pathogens to take advantage of host machinery.
Host pathogen interactions.
In evolutionary terms pathogenesis is the true “world’ s oldest profession”, since host  and pathogens have 
become to “negotiate” from the first event of phagocytosis. Starting from that point host  cells began to 
evolve, developing new metabolisms, organizing in more complexes structures (tissue, organ, organism), 
and erecting defenses from pathogens attack. The more specific and selective became host  defenses, the 
more pathogens had to evolve specific countermeasures. This challenge is still working leading to an un-
ceasing co-evolution of the two counterparts. Beside evolutionary aspects, this linked evolution have cre-
ated strict connections between host  and pathogens proteins: it  is possible to infer the function of some 
pathogens’ protein in the case its host  interacting protein has been identified, or understanding the activity 
of some pathogens’ protein could lead to uncover unknown cell activity. In fact many research advances 
in eukaryotic cell molecular biology have been done tanks to experimental research on cell parasites: for 
example Kalderon and coworkers were studying SV40 large T-antigen protein, usually located inside nu-
clear compartment  of expressing cells, while they uncover a T-antigen variant diffusely distributed inside 
expressing cell. The sequence analysis of this protein variant led to the identification of a short sequence 
capable of conferring nuclear localization to otherwise cytoplasmic proteins: they identified the first Nu-
clear Localization Sequence (NLS), an eukaryotic signal adopted by cell to address to nuclear environ-
ment nuclear acting protein (Kalderon et al. ’ 84. Cell.;39: 499). Similarly a few year later Malim and col-
leagues uncover the opposite mechanism, namely sequence mediated nuclear export, while they were 
working on HIV-1 Rev protein (Malim et al’ 89; Nature 338:254). Other cellular mechanism have been 
understood investigating mostly viral activity, leading to a deepest  knowledge of the cell at  a molecular 
level (Knipe and Holley, fields virology, 5th edition). Indeed one of the cellular process firmly necessary 
for viral replication is protein translation: no known virus codes a full set  of enzyme required form protein 
translation. Eukaryotic protein translation is an high controlled process, which could be represented es-
sentially as a three step process namely initiation, elongation and termination. Each process involves a 
different  set of proteins, which availability is regulated by intracellular or extracellular signals. The bot-
tleneck process is initiation process in which the 3’ and 5’ untranslated region of cellular mRNA are spe-
cifically recognized by initiation factors, namely eIF4F complex which recognize 5’ CAP structures and 
PABP a polyA binding protein whom accessibility is regulated by multiple phosphorylation pathway. 
Those proteins are also necessary for the docking to ribosome of the mRNA. Initiation step is obviously 
targeted by virus with the purpose of overwhelm eukaryotic specific mechanisms: influenza virus for in-
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stance steals host  5’ CAP sequences together with a proximal twenty nucleotides host  mRNA fragment, 
that is used to prime viral RNA synthesis. Moreover viral NS1 protein interacts with eIF4F complex to 
recruit  it  to viral mRNA (Plotch et  al. ’81 Cell 23: 847 , Dias et  al. ‘ Nature 458: 914 , Burgui et al. ‘ 07 j 
Virol. 81: 12427 ) resulting in a strong translation inhibition for most of the cellular mRNAs. Other vi-
ruses adopt a mimic strategy by encoding mRNA provided with 5’ CAP and polyA sequences. This is the 
case of herpesviruses which protein translation rely on CAP-dependent  translation; in fact HSV1 stimu-
lates eIF4F availability, by a activating degradation of its inhibitory subunit. Furthermore HSV1 encodes 
the multifunctional ICP6 proteins, which strengthen mRNA docking to initiation complex (Walsh et  al.’ 
06 Genes Dev. 20: 461 , Walsh et al. ‘ 04 , Genes Dev 18: 660, Walsh et  al. ‘ 08 , j Virol. 28:2648). The 
above described examples are exquisite representation of the intricate and intriguing field of host-
pathogen interaction. 
The growing knowledge of pathogens-cell interaction at molecular level, as wells as the growing tech-
nologies capability, supporting research field, are laying the foundations for the development of innova-
tive therapeutic approaches: pathogens proteins, or pathogens themselves are engineering in order to cre-
ate molecular tool to counteract different diseases. A fascinating approach has been illustrated very re-
cently in our city of Bologna by Campadelli-Fiume virology research group: they have engineered HSV-1 
virus in order to redirect its specific receptor recognition to another receptor, namely epidermal growth 
factor receptor type 2 (HER 2), highly expressed in high-grade glioma malignancy. Their modified virus 
are capable to tackle tumor growth, tumor proliferation and metastases spread in mice models (Nanni et 
al. 13, Menotti et al. ‘ 12).
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Abstract
Host-Pathogen Interaction is a very vast field of biological sciences, indeed every year many un-
known pathogens are uncovered leading to an exponential growth of this field. The present work 
lyes between its boundaries, touching different aspects of host-pathogen interaction: We have 
evaluate the permissiveness of Mesenchimal Stem cell (FM-MSC from now on) to all known 
human affecting herpesvirus. Our study demonstrate that FM-MSC are full permissive to HSV1, 
HSV2, HCMV and VZV. On the other hand HHV6, HHV7, EBV and HHV8 are susceptible, but 
failed to activate a lytic infection program. FM-MSC are pluripotent stem cell and have been 
studied intensely in last decade. FM-MSC are employed in some clinical applications. For this 
reason it is important  to known the degree of susceptibility to transmittable pathogens. Our atten-
tion has then moved to bacterial pathogens: we have performed a proteome-wide in silico analy-
sis of Chlamydiaceae family, searching for putative Nuclear localization Signal (NLS). Chlamy-
diaceae are a family of obligate intracellular parasites. It’s reasonably  to think that its members 
could delivered to nucleus effector proteins via NLS sequences: if that were the case the identifi-
cation of NLS carrying proteins could open the way to therapeutic approaches. Our results 
strengthen this hypothesis: we have identified 72 protein bearing NLS, and verified their func-
tionality with in vivo assays. Finally we have conceived a molecular scissor, creating a fusion 
protein between HIV-1 IN protein and FokI catalytic domain (a deoxyexonuclease domain). Our 
aim is to obtain chimeric enzyme (trojIN) which selectively identify IN naturally  occurring target 
(HIV LTR sites) and cleaves subsequently LTR carrying DNA (for example integrated HIV1 
DNA). Our preliminary results are promising since we have identified trojIN mutated version 
capable to selectively recognize LTR carrying DNA in an in vitro experiments.
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Chlamydiaceae Moves to the Nucleus: Whole 
Proteome Analysis Scanning for Nuclear Local-
ization Signals 
Abstract.
Chlamydiaceae family are composed by obligate intracellular bacteria. Like other intracel-
lular parasite they exploit cell machinery to their advantage. To date lot of Chlamydiaceae 
effector proteins have been identified acting inside host cytoplasm environment, but only a 
single recent work reported a nuclear acting protein. We believed that other unidentified 
Chlamydiaceae proteins could be redirected to nuclear compartment during infection. To 
confirm our hypothesis we performed an in silico analysis on each Chlamydiaceae pro-
teome in order to identify putative Nuclear Localization Signals (NLS): 72 proteins repre-
senting the 1% of the total amount have one or more putative NLS  embedded in their se-
quence. To test the predictively of our system we have analyzed the ability of two identified 
NLS to confer nuclear localization to the normally ubiquitous protein, GFP. 
INTRODUCTION
The family Chlamydiaceae comprises a diversified group of obligate intracellular Gram-negative 
bacteria infecting a wide range of different cell types in their eukaryotic hosts, including those of 
the eye, lung and genital tract epithelium, causing a variety of acute and chronic diseases 
(1,2,3,4). Chlamydiaceae are characterized by a biphasic cycle of development with spore-like, 
infectious Elementary Bodies (EB) and intracellular dividing, metabolically active Reticulate 
Bodies (RB), that inhabit a specialized parasitophorous (5) non-fusogenic inclusion separated 
from host cell cytoplasm by a double layered inclusion membrane (6). Chlamydiaceae have 
evolved adaptation strategies that fit them for thriving in a particularly hostile environment, the 
inside other cells: during infection, a temporally regulated gene expression program hits the host 
cell with successive waves of effector proteins that  modulate host cellular functions in coordina-
tion with the chlamydial infectious cycle and/or in response to cues from the host cell. Some of 
these effectors appear to significantly impact the cell cycle of infected cells, with evidence for 
cleavage of the mitotic cyclin B1 (7), delays in cytokinesis (8) and supernumerary centrosomes 
(9). It would be reasonable to expect that part of these host-interactive proteins may exert their 
function inside the cell nucleus, an easy prediction that is supported by a recent report showing 
that NUE, a Chlamydia trachomatis protein, migrates into the nucleus and methylates histones 
(10). Active nuclear import of chlamydial proteins has yet to be documented,  although it has al-
ready  been described previously for other bacterial proteins, leaving the open possibility  to un-
cover Chlamydial NLS: examples of prokaryotic proteins imported in cell nuclei are the Shigella 
flexneri effector OspF (11) and IpaH9.8 (12), Yersinia spp. YopM  (13), Xantomonas spp. 
AvrBs3-like proteins (14), VirD2 protein in Agrobacterium tumefaciens (15), the IgA1 protease 
in Neisseria gonorrhoeae (16) and the Ribosomal proteins in Thermus thermophiles (17) . 
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Nuclear import is a well regulated active pathways which is mediated by members of the karyo-
pherin family, a large, evolutionarily conserved family  of transport factors. Karyopherins interact 
directly  with their cargoes, although some also use adapter proteins. Karyopherins that mediate 
import bind to their cargoes in the cytoplasm via recognition of the nuclear localization signal 
(NLS), a short sequence embedded in the primary structure of cargo proteins. The 
karyopherin:cargo complex translocates through the NPC via interactions with NPC proteins 
(18). NLS signals were first identified and characterized on the SV40 Large T antigen and Nu-
cleoplasmin proteins, as one or two clusters of basic aminoacid residues separated by a linker, 
respectively (19) (see Tab. 1). The nuclear import of many proteins is mediated by these so called 
classic NLS. However evidence has accumulated for the existence of additional, non-classic im-
port signals unrelated to the basic NLS (18). In some cases, the NLS contains several basic 
amino acids as has been determined for core histones and ribosomal proteins. In other cases, the 
NLS domain is relatively  large, as in the case of M9 NLS, first identified in hnRNP A1 by Siomi 
and Dreyfuss (20). This non classic NLS consists of about 38 amino acids, is glycine rich, defi-
cient in basic amino acids and its nuclear transport is directly  mediated by Karyopherin-β2. Re-
cently Lee and coworkers have determined the M9NLS sequence necessary  and sufficient for 
proper Karyopherin-β2 recognition and subsequent nuclear import. Furthermore they  found that 
similar non classic sequence is found in other known Karyopherin-β2 binding proteins. Crystal-
lographic data of M9NLS peptide bound to Karyopherin-β2 together with mutagenesis analysis 
supported them in defining consensus sequences for M9 like NLS, reported in Table 1:
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FIG. 1 
Schematic representation of the constructs used in this study. Analyzed putative NLS se-
quences are listed in white boxes. The NLS coordinates in protein primary structure are 
GFPK+ NLS 391 PTTKRGRSGGEDARADALKKPK 413
GFP 790 KKRECAGGAIFAKRVR  805Bip-NLS
GFP 1385 VGPVRPTFYALHFNAA 1400DY-NLS
GFP 1385 VGPVRPTFYALHFNDY 1400AA-NLS
GFP 1385 VGPVRPTFYALHFNPY 1400PY-NLS
NLS prototype SubType Consensus
M9NLS/PY- 
NLS
Basic [KR]-X(0,2)-[KR]-[KR]-X(3,10)-[RKH]-X(1,5)-P-Y
Hydrophobic [AILMFWYV]-[GAS]-[AILMFWYVPKQR]-[AILMFWYVPKQR]
-X(7,12)-[RKH]-X(2,5)-P-Y
Canonical NLS Monopartite PX(1,3)[KR][KRH](0,1)[KR][KR][KR]
Bipartite K-[KR]-X(10,12)-K[KR]X(0,1)[KR]
M9NLS is a long and structurally disordered substrate, with an overall positive charge (or neutral 
at least). Its central domain could be hydrophobic or basic, defining the two subtypes of this 
NLS. Finally it  has C-terminal basic residue followed by an invariant PY sequence, after which 
this kind of NLS is named. PY-NLS consensus could be predictive for identifying unknown 
Karyopherin-β2 binding targets,(21). A recent work  has  observed a putative Bipartite NLS sig-
nal in Chlamydia trachomatis pmpD protein (22), supporting the hypothesis that some Chlamy-
diae protein actively transfer into their host  nuclear compartment. We report here for the first 
time an in silico whole proteome analysis on Chlamydia and Chlamydiophila species in order to 
identify putative NLS. In addition we have probed experimentally  verified the effective nuclear 
import of GFP protein fused either to the previously   reported Bipartite-NLS or to a PY-NLS, 
that we have identified in the present work, both occurring on the Chlamydia trachomatis pmpD 
protein. 
Material and Methods
Sequences Genesis. All mammalian constructs expressing GFP fusion proteins were generated 
using the Gateway  system (Invitrogen, Carlsbad, CA). Oligonucleotides including the attB1 and 
attB2 recombination sites were used as both primers and template to generate the sequences of 
interest by  fill-in reaction with GoTaq Taq polymerase (Promega, Madison, WI) as follows: 
p r i m e r s p m p D a t t B 1 ( 5 ' - G G G G A C A A G T T T G TA C A A A A A A G C A G C A G G 
CTTCGTTGGTCCTGTGAGACCTACTTTTTATGCGCATTTCAAT) and pmpD-PYattB2 
(5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAATAAGGATTGAAATGCAAAGCA
TAAAAAGTAGG) were used to obtain PY fragment, oligonucleotides pmpDattB1 and pmpD-
DYattB2 (5'-GGGG ACCACTTTGTACAAGAAAGCTGGGTCTTAATAGTCATTGAAATGCA 
AAGCATAAAAAGTAGG) were used to generate DY fragment, primers pmpDattB1 
(5'-GGGGACAAGTTTGTACAAAAAAGCAGCAGGCTTCGTTGGTCCTGTGAGACCTACT
Tab. 1 Consensus sequences for canonical and non canonical Nuclear Localiza-
tion Signals (NLS) under investigation in this work
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TTTTATGCGCATTTCAAT) and pmpD-AAattB2 (5'-GGGGACCACTTTGTACAA 
GAAAGCTGGGTCTTAAGCGGCATTGAAATGCAAAGCATAAAAAGTAGG) were used to 
g e n e r a t e A A f r a g m e n t . P r i m e r s p m p D - B i P a t t B 1 ( 5 ' -
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCAAAAGAAGAGAGTGTGCTGG) and 
p m p D - B i P a t t B 2 ( 5 ' - G G G G A C C A C T T T G TA C A A G A A A G C T G G G T C T T 
AACGAACCCGTTTTGCAAAAAT) were used to generate BiP sequence using purified Chla-
mydia Trachomatis serovar L2 genome as PCR template. Agarose-purified PCR products were 
introduced into the plasmid vector pDONOR207 (Invitrogen, Carlsbad, CA) via the BP recombi-
nation reaction, according to the manufacturer’s recommendations, in order to create the entry 
clones pDNR-PY, pDNR-DY and pDNR-AA and pDNR-BiP. Constructs were then used to per-
form LR recombination reactions with the Gateway system compatible expression (“DEST”) 
vector pEPI-DEST-GFP (23), according to products specifications, to express N-terminally 
tagged GFP fusion proteins. The integrity of all constructs was confirmed by DNA sequencing 
(PRIMM s.r.l., Milan).
Cell lines. African Green Monkey COS-7 cells were maintained in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 5% (v/v) fetal bovine serum, 50 units/mL penicillin, 50 
units/mL streptomycin, and 2 mM L-glutamine. For live imaging experiments, cells were 
trypsinized and 2x105cells were seeded onto coverslips in 24-well plates 1 day before transfec-
tion, which was performed using TransIT-LT1 (Mirus, Madison, WI) reagent according to the 
recommendations of the manufacturer.
ATP/GTP depletion assay.ATP/GTP pool have been depleted as reported previously by us (24): 
briefly 24 h after transfection COS7 expressing GFP fusion protein were treated s for 30 min at 
37 °C in DMEM  containing no glucose, 5% fetal bovine serum, and supplemented with 10 
mmol/L sodium azide and 6 mmol/L 2-deoxy-D-glucose (Sigma). After this treatment, the ATP 
intracellular levels were restored by replacing the energy depletion medium with DMEM, as 
used in normal growing conditions. Each experiment has been repeated three times.
Live imaging. Live COS-7 cells, grown on coverslip and expressing GFP fusion proteins, were 
imaged using a Nikon Eclipse TE2000-U inverted microscope  equipped with a Nikon DXN1200 
digital camera and a Nikon Plan Fluor 40× objective (Nikon Corp., Tokyo, Japan). Digital im-
ages were obtained using the NIS elements AR 2.30 software (Nikon Corp., Tokyo, Japan), using 
the following settings: gain, 50; offset, 0; acquisition times 500-2000 ms. Semiquantitative 
analysis of the levels of nuclear accumulation relative to each GFP fusion protein was performed 
using NIS elements AR 2.30 software to perform single cell measurements of the nuclear (Fn) 
and cytoplasmic (Fc) fluorescence, subsequent to the subtraction of fluorescence due to autofluo-
rescence/ background, to determine the nuclear to cytoplasmic fluorescence ratio (Fn/Fc). Local-
ization of each cell was classified on the basis of the Fn/Fc ratio as exclusively nuclear (N; Fn/Fc 
> 10), mainly nuclear (N > C; 10 > Fn/Fc > 2), or diffuse (D; 2 > Fn/Fc > 1). At least 100 GFP 
expressing cells were analyzed for each fusion protein. Each experiment has been repeated three 
times.
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In silico analysis. Bioinformatic analysis was performed essentially as described  by others (21): 
briefly proteome sequences of C. trachomatis serovar D, C. pneumoniae , C. psittaci, C. murida-
rum, C. caviae , C. abortus , C. felis, C. suis and C. pecorum, were obtained from UniProtKB 
database (25). Proteins carrying putative NLS were identified by subjecting each proteome to 
ScanProsite software, searching NLS motifs listed in tab. 1. All resulting entries were filtered for 
structural disorder using DisEMBL tool (26) and for an overall positive charge surrounding NLS 
sequence. PY-NLS overall positive charge were determined analyzing the sequence encompass-
ing 40 aminoacid N-terminal to PY domain and 10 aminoacid C-terminal to it. Only NLS bear-
ing proteins sharing some degree of homology with ortholog/paralog or proteins belonging to 
autotransporter’s protein family were selected. Ribosomal proteins, protein elongation factors, 
signal transducers and ion carriers were removed from NLS-bearing protein list.
Results. 
NLS  prediction in Chlamydiaceae. We have performed an in silico analysis on the proteome of 
nine Chlamydiaceae species, scanning for putative NLS sequences matching the reported con-
sensus for classical and PY NLS (Tab.1) (19): we have identified 336 proteins bearing potential 
NLS, representing the 5% of the total analyzed proteins. Subsequently we restricted the number 
of NLS candidates by analyzing molecular disorder and the overall charge of the sequence sur-
rounding each NLS; furthermore we have excluded known  nucleic acid interacting proteins (see 
material and methods section): the resulting 72 proteins with putative NLS, representing about 
1% of all analyzed proteins are listed in table 2.
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 Fig.2 Bip NLS Translocate GFP into Nucleus.
A) Live imaging analysis of COS7 cells transfected with the indicated GFP fusion protein. Pictures 
are representative of typical subcellular localization. 
B) Semi quantitative analysis of relative mean fluorescence (R.M.F.) of analyzed GFP fusion pro-
teins.
B)A)
Identified NLS are functional. 
We have evaluated the predictability  of our selection system analyzing the actual nuclear import 
of two identified NLS, N-terminally fused to GFP protein (see fig.1 for a schematic construct 
representation). Interestingly, the selected NLS are both present on the same protein, namely 
Chlamydia trachomatis pmpD protein, and respond either to classic or PY reference sequences. 
Our choice fell on pmpD for several reasons: pmpD belongs to the type V or autotransporter 
secretion pathway, the most widespread secretion mechanism employed by  gram-negative bacte-
ria to deliver virulence factors (27). Furthermore it has been suggested that late in infection, 
pmpD could be processed and released into the cell cytosol (28), becoming a perfect candidate 
for nuclear import. The canonical NLS is a putative bipartite NLS  (Bip from now on), previ-
ously  observed by  Swanson and coworkers (22),  carried by a 30kDa soluble peptide produced 
upon pmpD auto-processing. As clearly observable in fig. 2, Bip  sequence is sufficient to  confer 
nuclear localization to its fusion partner, the otherwise ubiquitous GFP protein. Furthermore nu-
clear localization of GFP-Bip  fusion protein  is inhibited after GTP pool depletion (fig. 3), sug-
gesting that observed nuclear import is due to an active process (24) rather than a passive 
mechanism. 
FIG. 3 Triphosphate depletion assay. Live imaging analysis of COS7 
cells expressing GFP, GFP-K+ and GFP-Bip, during ATP/GTP deple-
tion assay (ATP-) and the subsequent restoring of physiological condi-
tions (Restore). Control untreated samples was also observed (N.T.). 
For each sample pictures are representative of their typical subcellular 
localization.  
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The selected PY NLS sequence is a hydrophobic PY NLS and is  embedded in the pmpD C-
terminal translocation domain (TD) fragment. Little is know about the pmpD TD processing fate 
during infection. Curiously, while the Bip NLS is not conserved in other members of the Chla-
mydiaceae, a PY NLS was also identified in two pmp  paralogues of C. pneumonie suggesting an 
unknown conserved function for this sequence. Fig.4 shows that PY-GFP fusion protein localizes 
in the nucleus of expressing cells. In parallel we analyzed subcellular localization of GFP-DY 
and GFP-AA fusion proteins, in which respectively  P or PY residues are mutated in order to 
abolish Karyopherin-β2 recognition sequence. Both fusion proteins show a diffuse subcellular 
localization, comparable with that corresponding to GFP alone. We could infer that the identified 
PY is a bona fide functional NLS, necessary to GFP nuclear import. 
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Fig.4 PY NLS Translocate GFP into Nucleus.
A) Live imaging analysis of COS7 cells transfected 
with the indicated GFP fusion protein.  Pictures are 
representative of typical subcellular localization. 
B) Semi quantitative analysis of relative mean fluo-
rescence (R.M.F.) of analyzed GFP fusion pro-
teins.
Discussion.
Members of the Chlamydiaceae family  are obligate intracellular pathogens, and have evolved 
several strategies and mechanisms to exploit cellular machinery: in fact several chlamydial pro-
teins are inserted into the inclusion membrane or secreted into the host  cytoplasm. Those proteins 
are capable of interacting with members of the cellular machinery: for example they modify  host 
cell cycle phase (7), they  prevent host cell apoptosis (29), or inhibit  NF-Kb signaling pathway, 
stabilizing IkB protein (30). Chlamydial effector proteins working  within the cell cytoplasm 
have been deeply documented while only a recent single report demonstrated a nuclear activity 
for C.trachomatis NUE protein which interacts with cell histone proteins: this is the first docu-
mented Chlamydiaceae nuclear protein (10). Although the Authors have not “formally” charac-
terized yet the NLS required for NUE nuclear import, they demonstrated that  a NUE protein de-
prived of two separated basic residue stretches failed to accumulate in the cell nucleus, suggest-
ing that inside removed sequences could resides a yet unidentified functional NLS. Although a 
vastly  unexplored field, bacterially encoded proteins that localize into cell nuclei represent an 
innovative field to better understand host-pathogens interplay. Moving in that direction we have 
performed an in silico analysis of all known Chlamydiaceae proteomes, scanning for conserved 
putative NLS. We have identified 72 proteins with one or more putative NLS representing the 
1% of the 7066 analyzed. Intriguingly about 40% of identified NLS carrying proteins belong to 
the autotransporter protein family,  whose members typically translocate in the pathogen outer 
membrane where they often release an active protein inside the cell cytoplasm by self processing 
of the full length protein. NLS occurring on autotransporter suggest a fascinating hypothesis: 
chlamydiae could have implemented an autotransporter system including effector proteins en-
dowed with NLS , in order to  allow their translocation in the nucleus of host cells, where they 
may interfere with the regulation of cellular functions, for example via epigenetic reprogram-
ming, as the methylation of histones by NUE would suggest.  
Furthermore we have verified the ability of two, among identified NLS, to confer nuclear local-
ization to GFP protein, which normally appears diffuse ubiquitously in expressing cells. The se-
lected NLS occur in two different domains of C.trachomatis pmpD, an autotransporter protein 
highly  conserved among trachomatis serovars, which suggests the idea that pmpD exerts  an es-
sential although as yet unknown function. One NLS is a classical Bipartite NLS (19), inserted in 
the Passenger Domain, the secreted effector of pmpD protein. Our results demonstrated that it is 
capable to confer nuclear destination to GFP protein; furthermore we have demonstrated that 
GFP-Bip nuclear import  is an active transport, which suggests that nuclear import is mediate by 
the Bip NLS, as reported before (24). The other selected NLS is a PY NLS which is embedded 
into the pmpD Translocation Domain. While the former domain is known to be processed and 
secreted into the cytoplasm during chlamydia infection, the latter theoretically would remain 
membrane associated (28,22). In contrast we have found that GFP-PY fusion protein accumu-
lates in the nuclei of expressing cells. Furthermore mutant fusion protein with abolished PY se-
quence failed to be actively  imported beyond the nuclear envelope, showing a diffuse subcellu-
lar localization. Taken together these results suggest that  the identified NLSs are functional. In 
order to confirm actual NLS functionality, we need to demonstrate effective physical interaction 
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between GFP-NLS fusion protein and related cellular transporter (karyopherins). Furthermore it 
will be also necessary  to identify during infection an NLS associated peptides inside the nuclear 
environment.
In this study we have identify 72 Chlamydiaceae proteins bearing one or more NLS signals. This 
could be the starting point for the discovery of  additional unknown nuclear activities of Chla-
mydiaceae' s proteins. In turn, uncovering new nuclear localizable effector functions would shed 
light on the complex interaction between host cell and chlamydiaceae.
Protein
Chlamydia/
Chlamydiophila 
species (IDprot)
NLS
http://prosite.expasy.org/scanprosite/
Function/
Membrane/
Secretion
http://www.uniprot.org/
K-[KR]-X(10,12)-
K[KR]X(0,1)[KR]
10 kDa chaperonin
 caviae (P15598) KKqdraevlvlgtgKRdK 40 – 57 chaperon, protein fold-
ingpsittaci (F0T4F9) KKqdraqvlalgtgKRdK 40 – 57
abortus (Q6YNR5) KKqdraevlalgtgKRdK 40 - 57
Serine/threonine-protein kinase pknD
caviae (Q822K5)  * KRiredlsdnell.KK.R 33 – 48
protein kinase
abortus (Q5L5J7)
psittaci (F0T4J3) KRirkdlsdnell.KK.R 33 – 48
pneumoniae (Q9Z986) * KKiredlaenpll.KR.R 33 – 48
 Polymorphic outer membrane protein 
Polymorphic membrane protein D
trachomatis serD (D7DET2)  
*
KRrecaggaifa..KRvR 790 - 805 autotransporter
suis (B8YPF0) * KRrecaggaifa..KRvR 783 - 798 autotransporter
UPF0235 protein CCA_00247
UPF0235 protein CAB243
UPF0235 protein G5S_0576
caviae (Q824A6) KRdvtlisgetsr.KK.R  58 – 73
abortus (Q5L6M2) KRditlipgdtsr.KK.R 58 - 73
pecorum (F4DL14) KRdvtlvsgessr.KK.K 69 – 84 
FtsK trachomatis serD (D7DEL2) KRnvhrpeslleelKK.K 334 - 350 Integral to membrane, cell division.
Type III secretion chaperone SycD 
LcrH
Type III secretion chaperone SycD
Putative uncharacterized protein 
lcrH_1
caviae (Q821I8) * KKtrsrlaelaaq.KKaK  18 – 34KKkkataaksktadKK.K  206 – 222
response to stress
pneumoniae (Q9Z795) KKtrsrlaelaaq.KKaK 21 – 37
Psittaci (F0T5A6) KKtrsrlaelaaq.KKaK 18 – 34
trachomatis ser D 
(D7DE48) KKsrsrlaeiaaq.KKaK 18 – 34
Protein translocase subunit, putative
Protein translocase subunit 
Protein translocase subunit 
Protein translocase subunit
Putative uncharacterized protein
Preprotein translocase subunit-like 
protein
caviae (Q823A4)  KKinrndpcpcgsnKKyK  3 – 20
pecorum (F4DIZ8)
pneumoniae (Q9Z8S8) KKinrndlcpcgsnKKyK 3 – 20
psittaci (F0T453)
KKvnrndpcpcgsnKKyK 3 – 20
abortus (Q5L5X1)
trachomatis (D7DCW3)  KKpnrndpcpcgsgKKyK 3 – 20
Hypothetical membrane associated 
protein trachomatis (D7DEK7) * KKksscylrkffsrKKpK 57 – 74
Putative uncharacterized protein
Phosphohydrolase
Putative exported protein
caviae (Q824I3) KRqlyvnrglggf.KRlR 292 – 308
 hydrolase activitypsittaci (F0T357)
KKqlyvnrglggf.KRlR 292 – 308
abortus (Q5L6V1)
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Putative uncharacterized protein
trachomatis (D7DEE3)
KKdrvdraekvvkeKR.R  13 – 29 caviae (Q824V3)
pneumoniae (Q9Z7J9)
psittaci (F0T5K1) KRdrvdraekvvkeKR.R 13 – 29
pecorum (F4DKF7) KKdrvdraekivkeKR.R 13 – 29
Putative uncharacterized protein
caviae (Q821R6) * KKtkelsaeaell.KKlR  4 – 20 KKlrdkalvleeqkKR.K 17 – 33
psittaci (F0T526) * KKtkelsaeaell.KKlR 4 – 20KKlrdqalileeq.KK.R 17 – 32
abortus (Q5L516) *
KKydflrfrgmgt.KKiK 3 – 19
KKikelsaeaell.KKlR 16 – 32
KKlrdqalaleeq.KK.R 29 - 44
PX(1,3)[KR][KRH](0,1)[KR][KR][
KR]
Serine/threonine-protein kinase pknD
pneumoniae (Q9Z986) * Py.RRKK 229-234 
protein kinase
trachomatis ser D 
(D7DDC2)                    Py.RRKK 235-240 
muridarum (Q9PK92)
caviae (Q822K5) * Py.RKKK  230 – 235
General Secretion Protein F pneumoniae (Q9Z789) PkeRRKR 11 - 17 Type II protein secretion system
Uncharacterized protein TC_0273 muridarum (Q9PL35) PspRRKK 355 - 361 Integral to membrane
Preprotein translocase, YajC subunit
UPF0092 membrane protein 
CPn_0884
Conserved membrane protein
pecorum (F4DJZ1)  *  PeqKRRK 51 - 57
Integral to membrane
caviae (Q821Q4) *
PeqKRRK 52 - 58psittaci (F0T538) *
pneumoniae (Q9Z722)
abortus (Q5L504) *
SET domain containing protein
Putative uncharacterized protein
pecorum (F4DJZ6) PlywKHRKK 201 - 209
hystone metilation
trachomatis ser D 
(D7DEL0) PlywKHRKK 202 - 210
pneumoniae (Q9Z728) PlywKHRKK 204 - 212
psittaci (F0T543)
PlywKHRKK 203 - 211"abortus (Q5L4Z8)
caviae (Q821Q0)
muridarum (Q9PLI9) PlywKHRKK 202 - 210
Negative regulator of genetic compe-
tence clpC/mecB
Endopeptidase Clp ATP-binding chain 
clpC
Probable ATP-dependent Clp protease 
ATP-binding subunit
Negative regulator of genetic compe-
tence clpc/mecb 
ATP-dependent Clp protease ATP-
binding subunit
trachomatis ser D 
(D7DDA7) PealR.KKR 257 - 264
chaperone, nucleotide-
excision repair
pecorum (F4DIH4) PealR.KKR 255 - 262
muridarum (Q9PKA8) PealR.KKR 274 - 281
pneumoniae (Q9Z8A6) PdalR.KKR 255 - 262
abortus (Q5L6D0)
PdtlR.KKR 254 - 261caviae (Q823Q2)
psittaci (F0T3N8)
16
Putative uncharacterized protein 
Putative uncharacterized protein 
CPj0350
trachomatis ser D 
(D7DCN8) PrgsK.KRR 106 - 113
-
abortus (Q5L656) PrgsK.KRR 86 - 93
muridarum (Q9PKX4) PrgsK.KRK 83 - 90
pecorum (F4DIQ7)
PrgsK.KRR 83 - 90
caviae (Q823H4)
psittaci (F0T3W8)
pneumoniae (Q9Z8J3)
[KR]-X(0,2)-[KR]-[KR]-X(3,10)-
[RKH]-X(1,5)-P-Y
Hemolysin (Putative uncharacterized 
protein CPj0395)
CBS domain protein, putative
CBS domain protein
CBS domain protein
Putative membrane transport protein
pneumoniae (Q9Z8E8)
KdhKKaryinfli..Rr....PY 43 - 59 FAD-binding
psittaci (F0T3T4)
caviae (Q823K9)
pecorum (F4DIM1)
abortus (Q5L690)
Peptide ABC transporter, periplasmic 
peptide-binding protein, putative muridarum (Q9PKJ4) Ke.KKdrrwlkle..Kn....PY 201 – 216 transporter activity
Peptide ABC transporter, permease 
protein
muridarum (Q9PKJ3) LAYAkglsplkvlik.Hvl...PY 207 – 226 Transmembrane, trans-
porter activitypsittaci (F0T4C2) LAYAkglspikvilk.Hil...PY 207 - 226
Peptide ABC transporter, permease 
protein pecorum (F4DJ73) *
  KknKKnkkqphtqe.Kan...PY  327 - 
345
Transmembrane, trans-
porter activity
Oligopeptide Permease pneumoniae (Q9Z8Y5) * LAYAkglsplkvvik.Hil...PY 207 - 226 Transmembrane, trans-porter activity
Oligopeptide ABC transporter per-
mease protein pneumoniae (Q9Z7V7) *
WGQPedlciayanvekRae...PY 270 - 
290
Transmembrane, trans-
porter activity
OppA
trachomatis ser D 
(D7DD20) *
Ke.KKdrrwlkle..Ks....PY 199 - 214 
 KkdRRwlkle.....Ks....PY 201 - 214
Kd.RRwlkle.....Ks....PY  202 - 214
Transporter activity
Putative ABC transporter, ATP-binding 
component
Peptide ABC transporter, ATP-binding 
protein
abortus (Q5L6G4) ReiKKlqpqelk...KsniqrPY 288 - 307
ABC type 1 transporter
psittaci (F0T3K3)
ReiKKlqpqelk...KsniqrPY  284 - 303
pneumoniae (Q9Z9F8)
muridarum (Q9PK46)
pecorum (F4DIE1)
caviae (Q823U0)  ReiKKlqpqelk...KsniqrPY  296 - 315
ABC Transporter Protein ATPase muridarum (Q9PLN7)
 AGRMaeyssvqdif..Hspah.PY  232 - 
252                                         
peptide transporter ac-
tivity
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[AILMFWYV]-[GAS]-[AILMFWY
VPKQR]-[AILMFWYVPKQR]-X(7
,12)-[RKH]-X(2,5)-P-Y
Probable outer membrane protein 
pmp19 pneumoniae (Q9Z813)
LSLRssfsytedsqvmKhvf..PY 758 - 
779
Cell outer membrane,
Autotransporter
Probable outer membrane protein 
pmp2 pneumoniae (Q9Z3A1) ASLYsvvsillgegglReill.PY 619 - 641
Cell outer membrane,
Autotransporter
Polymorphic  outer membrane protein 
pmpD
Polymorphic membrane protein D
Probable outer 
membrane protein pmpD
trachomatis ser D 
(D7DET2) * VGPVrptfyal.....Hfn...PY 1385 – 1400
Autotransporter
suis (B8YPF0) * VGPVrptfyal.....Hfn...PY 1377 - 1392
muridarum (Q9PLB0) VGPArpkfyal.....Hfn...PY 1367 - 1382
Probable outer membrane protein 
pmpA muridarum (Q9PJY3) ASLPrnnsilv.....Kes...PY 408 - 423 Autotransporter
Outer membrane protein, putative muridarum (Q9PKF3) VSFAvhptlpvydvtyRvsegaPY 333 - 356 Outer membrane
Hypothetical membrane associated 
protein
trachomatis ser D 
(D7DD25) VALIqelietp.....Hvn...PY 145 - 160
-
CBS domain containing protein
Putative uncharacterized protein
CBS domain-containing protein
Putative membrane transport protein
CBS domain protein
trachomatis ser D 
(D7DD78) VGVPlaltlvlgeivpKviai.PY 92 - 114
FAD-binding"
muridarum (Q9PKD8)  VGVPlaltlvlgeiipKviai.PY 92 - 114
psittaci (F0T3T5)
VGFPlaltlvlceilpKaval.PY 92 - 114abortus (Q5L689)
pecorum (F4DIM2) VGIPltitlifgevlpKaval.PY 91 - 113
Predicted permease
Putative uncharacterized protein
Conserved hypothetical membrane 
protein
YjgP/YjgQ family protein
YjgP/YjgQ family protein
Putative uncharacterized protein
trachomatis ser D 
(D7DEV9)
ISIIsslqeivsyia.Kdv...PY 26 - 45
integral to membrane
muridarum (Q9PL80)
psittaci (F0T4S8)
abortus (Q5L5B1)
caviae (Q822B8)
pecorum (F4DJN7) ISIIsslqeivvyia.Kdv...PY 26 - 45
pneumoniae (Q9Z6R3) ISIIsslqeivayia.Kdv...PY 26 - 45
Arginine/agmatine antiporter
trachomatis ser D 
(D7DDJ6) LSLVrpdlkagiytysRegfg.PY 67 - 89
Cell inner membrane, 
aminoacid transport
muridarum (Q9PK20)
psittaci (F0T4P4)
LSLVrpdlttgiymysRegfg.PY 67 - 89caviae (Q822F2)
abortus (Q5L5E6)
Chaperone protein DnaK
trachomatis ser D 
(D7DDL8)  IGRKfsevesei....Ktv...PY 81 - 97 
                                   78 - 94                
chaperone, protein fold-
ing
muridarum (P56836)
psittaci (F0T3D1)
IGRKysevesei....Ktv...PY 78 – 94
abortus (Q8GH79)
caviae (Q824B2) IGRKhsevesei....Ktv...PY 78 – 94
OppB trachomatis ser D (D7DD21) LAYAkglspfkvlik.Hil...PY 207 - 226
integral to membrane, 
transporter activity
OppD trachomatis ser D (D7DEG3)
AGRMaeyssvqeif..Hspah.PY 232 - 
252 ABC transporter
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Transcription-repair coupling factor
trachomatis ser D 
(D7DEM0) AALKhkqkpmlfhddiKief..PY 940 - 961
DNA repair
psittaci (F0T531) AALKnnsspllfnddvKief..PY 940 - 961
abortus (Q5L511) AALKnnsspllfnddvKief..PY 942 - 963
caviae (Q821R1) AALKnnttpllfnddvKief..PY 942 - 963
pecorum (F4DJY3) * AALKthsspsllqdtiKief..PY 926 – 947LSIQqthgkneli...Kqtl..PY 1024 - 1042
Virulence plasmid protein pGP6-D-
related protein
PGP6-D chromosomal paralog
muridarum (Q9PJF7) FSAWllltygn.....Rqt...PY 110 - 125
-psittaci (F0T5B3)
caviae (Q821I1) FSAWllitygn.....Rqt...PY 110 – 125 
2-oxoisovalerate dehydrogenase alpha 
subunit
Oxoisovalerate Dehydrogenase Alpha/
Beta Fusion
Putative oxidoreductase
2-oxoisovalerate dehydrogenase, E1 
component, beta subunit
2-oxoisovalerate dehydrogenase, E1 
component, alpha and beta subunit
trachomatis ser D 
(D7DDG2) *
AGVVaakslipg....Kdwaf.PY 52 - 70
ASFLarttqnhsag..Rmm...PY 89 - 107
Oxidoreductase
pneumoniae (Q9Z9E8) *
AGVLagkslipg....Kdwsf.PY 52 - 70
ASFLarttpnhssa..Rmm...PY 89 - 107
YAYLdapirrlggl..Hapv..PY 634 - 653
abortus (Q5L6F6) *
VGVVagksllrg....Kdwsf.PY 52 – 70
ASFLgrlapnhssg..Rmm...PY 89 – 107
YAYLdapirrvagl..Hapv..PY 634 - 653
psittaci (F0T3L1) *
VGVVagkslipg....Kdwsf.PY 52 – 70
ASFLarlapnhssg..Rmm...PY 89 – 107
YAYLdapirrvagl..Hapv..PY 634 - 653
muridarum (Q9PK54) * AGVVaakslipg....Kdwaf.PY 52 - 70ASFLarttqnhsdg..Rmm...PY 89 - 107
caviae (Q823T1) *
AGVIagkslipg....Kdwsf.PY 52 – 70
ASFLarltpnhssg..Rmm...P 89 – 107
 YSYLdapirrvagl..Hapv..PY 634 - 653
pecorum (F4DK12) * AGIVagksllpe....Kdwsf.PY 24 – 42VAAFlartssnhssg.Rmm...PY 60 - 79
Cell shape-determining protein  MrdB, 
putative
Cell shape-determining protein MrdB
Putative cell shape-determining protein
muridarum (Q9PLK0) LGMLcsllifsgiip.Hdtvk.PY 199 – 220
Integral to membrane, 
cell cyclecaviae (Q821N9) LGMLcsllifsgiis.Hekvk.PY 199 - 220
psittaci (F0T554) AGMLcsllifsgiis.Hekvk.PY 178  - 199
ABC ATPase
Oligopeptide ABC transporter, ATP-
binding protein
Peptide ABC transporter, ATP-binding 
protein
pneumoniae (Q9Z7M2) AGRMvecapavqmf..Hnpsh.PY 232 – 252 
peptide transporter ac-
tivity
psittaci (F0T5M4) AGRLaecapvkdif..Hnpch.PY 232 – 252
caviae (Q824T1) AGRKaeyasakeif..Hnpch.PY 232 - 252
Peptide ABC transporter, ATP-binding 
protein psittaci (F0T4C5) LSVLrlvnlplsvl..Rlk...PY 116 - 134 ABC transporter
RodA trachomatis ser D (D7DEJ9) LGMFcsllifsgiip.Hdkvk.PY 199 - 220
Integral to membrane, 
cell cycle
Oligopeptide Permease pneumoniae (Q9Z8Y5) * LAYAkglsplkvvik.Hil...PY 207 - 226 Integral to membrane, transporter activity
Oligopeptide ABC transporter per-
mease protein pneumoniae (Q9Z7V7) *
WGQPedlciayanvekRae...PY 270 - 
290
Integral to membrane, 
transporter activity
Type III secreted protein SctW pneumoniae (Q9Z8L4) MAIVssflmkgmatelKrqg..PY 233 - 254
Outer membrane, type 
III  protein secretion 
system
Oligopeptide ABC transport system 
substrate-binding protein oppA pneumoniae (Q9Z8Y7)  LAFPafaifkpenp..Klfsg.PY 155 - 175
Transporter activity
Rod Shape Protein
Putative rod shape-determining protein
pneumoniae (Q9Z739) IGIIgsllifsgivs.Hqkvk.PY 235 - 256 Integral to membrane, 
cell cycleabortus (Q5L4Y7)" MGMLcsllifsgmis.Hekvk.PY 199 - 220
CT131 homolog-(Possible Transmem-
brane Protein) pneumoniae (Q9Z8Z5) FSLPldsitktygkqvRls...PY 627 - 647 Integral to membrane
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UvrABC system protein A trachomatis (O84337) ASALeisemleslft.Righ..PY1033-1053
ABC type 1 transporter
(2 domains)
Cationic Amino Acid Transporter pneumoniae (Q9Z954) ASLAptavlyhsntkqKel...PY 112 - 132 Membrane
Putative uncharacterized protein muridarum (Q9PJW7) LGRPlskgcgrsdccqKkksc.PY 29 - 51 Membrane
Putative uncharacterized protein
Uncharacterized protein TC_0306
trachomatis serD (D7DCK8) FALLvsvvsffgcq..Kli...PY 63 - 81 -
muridarum (Q9PL02) LALLvsvisffgcr..Kli...PY 64-82 transmembrane
Putative zinc metalloprotease 
CPn_0344/CP_0416 pneumoniae (Q9K275) FSRQprvlasvl....Hyt...PY 281-297
transmembrane, metal-
loprotease
Uncharacterized protein CPn_0442 pneumoniae (Q9Z8A1) LGLLmsvttsvtlfqvHknlfpPY 122-145 transmembrane
60 kDa chaperonin 2
60 kDa chaperonin
psittaci (F0T5D4) LGPQgscvvikkd...Rvs...PY 30 - 47
chaperone, protein fold-
ing
caviae (P59698) LGPQgshvvikkd...Hss...PY 30 - 47"
abortus (Q5L4Q8) * LGPQgscvvikkd...Rms...PY 30 – 47AGKVpdavvatvle..Had...PY 459 - 477
Putative conserved membrane protein
Lipoprotein, putative
Putative uncharacterized protein
abortus (Q5L5B8) LSLIlgvlfcyke...Kipn..PY 211 - 229
-psittaci (F0T4S1) LSLMlgvlfcyke...Kipn..PY 211 - 229
caviae (Q822C5)
pecorum (F4DJN0) LGLAwlfckke.....Kipn..PY 213 - 229
ABC transporter, permease protein, 
putative
psittaci (F0T340) FSRYirietlkq....Rnm...PY 454 - 470 Integral to membrane, transporter activity
Lipoprotein releasing system trans-
membrane protein 
ABC transporter, permease protein
Permease, putative
abortus (Q5L5W5) FSQFiaypsdevykn.Rvl...PY 177 - 196
Integral to membrane, 
transporter activitypsittaci (F0T459)
FSQFiaypsdevyqn.Rvl...PY 177 – 196
caviae (Q822Z8)  FSQFvaypsdevyks.Rvl...PY 177 - 196
Putative ABC transporter peptide peri-
plasmic binding lipoprotein
psittaci (F0T4B9)
LGQPwhqgltkel...Kent..PY 230 - 248
Transporter activityabortus (Q5L5R9)
caviae (Q822T0) LGQPwhqgltkel...Kett..PY 238 - 256
Peptide ABC transporter, periplasmic 
binding protein caviae (Q822S8)  LGIRaidkstleitleKpi...PY 166 - 186 Transporter activity
Putative peptide ABC transport ATP-
binding protein abortus (Q5L751)
AGRLaeyapvkdif..Hnpch.PY 232 - 
252 Transporter activity
Putative uncharacterized protein
psittaci (F0T3Q3) WAFFsppsnfykq...Rfst..PY 37 - 55
-caviae (Q823N7) WAFFsppnnfhkq...Rfst..PY 67 - 85
abortus (Q5L6B6) WAFFsppsnfhkq...Rfst..PY 67 - 85
pecorum (F4DII8) WAMFsppenfykq...Rfst..PY 67 - 85
Polymorphic outer membrane protein H 
family
Polymorphic outer membrane protein
psittaci (F0T3G3) IGLAfgqlygqv....Ksk...PY 741 – 757 Outer membrane
Transporter activityabortus (Q5L6J8) IGLAfgqlygqv....Ksk...PY 737 - 753
Extracellular solute-binding protein Psittaci (F0T338) ASKRmdlyhrfhevi.Hees..PY 593 - 613 Transporter activity
Putative peptide ABC transport system 
permease protein
Peptide ABC transporter, permease 
protein
abortus (Q5L5R6) LAYAkglspikvilk.Hil...PY 207 - 226
Integral to membrane, 
transporter activity
caviae (Q822S7)  LAYAkglspikvilr.Hil...PY 207 – 226
pecorum (F4DJ73) * FAYAkglpplkvilk.Hvl...PY 225 – 244
Outer membrane protein 11 pecorum (F4DJR8) LGFLfrkdpqlei...KpliglPY 84 – 104 autotransporter
Amino acid permease pecorum (F4DJK1) LSQVrpdltagiymysRkgfg.PY 67 - 89
amino acid transmem-
brane transporter activ-
ity
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[ K R ] X [ K R ] [ K R ] [ K R ] X
K
DNA-directed RNA polymerase subunit 
beta
psittaci (Q5MIL2)
RkKRRrK 187 - 193 transcriptionabortus (Q5L5I3)
caviae (Q822J1)
Holliday junction resolvase-like protein
Putative Holliday junction resolvase
Putative Holliday junction resolvase
psittaci (F0T4B8)
RkKRKgK 122 – 128 DNA recombination / 
repairabortus (Q5L5S0)
caviae (Q822T1) RkKRKgK 124 – 130
Putative nucleoside triphosphate trans-
port protein 2
ADP, ATP carrier protein
abortus (Q5L6Y7)
KaKKKtK 280 - 286 Integral to membrane, 
ATP:ADP antiporter 
activity
psittaci (F0T323)
caviae (Q824L9)  KaKKKtK 277 - 283
pecorum (F4DKP4) KaKKKvK 272 - 278
Putative uncharacterized protein
Putative inner membrane protein
caviae (Q823W5) RrRKRkK 374 – 380
-psittaci (F0T3I0) RkKRKkK 372 - 382
abortus (Q5L6I7) RdRKKrK 399 – 405 RkKRKkK 401 - 407
ABC transporter, periplasmic substrate-
binding protein, putative pecorum (F4DJA0)
KwKRRqK 189 - 195 -
[ K R ] [ K R ] X ( 3 ) [ K R ] [ K R
] K
Hypothetical membrane associated 
protein
trachomatis ser D 
(D7DFA6)
trachomatis ser D 
(D7DEK7) *
RKffsRKK 65 - 72 -
Putative uncharacterized protein
psittaci (F0T314) KKkqgRKK 149 – 156
-abortus (Q5L6Z6) KKkqgRKK 149 - 156
caviae (Q824M8) KKkqgRKK  151 - 158
Conserved membrane protein
Preprotein translocase subunit
Preprotein translocase, YajC subunit
Preprotein translocase, YajC subunit
abortus (Q5L504) *
RKameKRK 57 - 64 Integral to membranepsittaci (F0T538) *
caviae (Q821Q4) *
pecorum (F4DJZ1)  * RKaaeKRK 56 – 63
Efflux protein, putative caviae (Q824X9) KKvsyRRK 551 - 558  transmembrane trans-port
Tab. 2 Identified NLS carrying ptotein. The identified NLS bearing proteins are reported, In Yellow boxes are 
reported autotransporter proteins.  Analyzed C.trachomatis pmpD NLS are higlited in red. LEGEND: * identify 
proteins bearing two or more differend kind of NLS; *  identify proteins bearing  two or more NLS of the same 
Kind. Identified NLS bearing proteins are listed by mean of consensus sequence.
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ABSTRACT
Fetal membrane (FM) derived mesenchymal stromal/stem cells (MSCs) are higher in number, and have greater 
expansion and differentiation abilities compared with those obtained from adult tissues, including bone marrow. 
Upon systemic administration, ex vivo expanded FM-MSCs preferentially home to damaged tissues promoting re-
generative processes through their unique biological properties.  These characteristics together with their immuno-
privileged nature and immune suppressive activity,  a low infection rate and young age of placenta compared to 
other sources of SCs make FM-MSCs an attractive target for cell-based therapy and a valuable tool in regenerative 
medicine,  currently being evaluated in clinical trials. In the present study we investigated the permissivity of FM-
MSCs to members of the Herpesviridae family, an issue which  is relevant to their purification, propagation, con-
servation and therapeutic use,  as well as to their potential role in the vertical transmission of viral agents to the fe-
tus and their use in viral vector-mediated genetic modification. We present here evidence that FM-MSCs are fully 
permissive to infection with Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), Varicella zoster virus (VZV),  and 
Human Cytomegalovirus (HCMV), but not with Epstein-Barr virus (EBV), Human Herpesvirus-6, 7 and 8 (HHV-
6, 7, 8) although these viruses are capable of entering FM-MSCs and transient, limited viral gene expression oc-
curs. Our findings therefore strongly suggest that FM-MSCs should be screened for the presence of HSVs, HCMV 
and VZV before xenotransplantation. In addition, they suggest that herpesviruses may be used as viral vectors for 
transient gene expression in MSCs both in gene therapy applications and in the selective induction of differentia-
tion.
25
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INTRODUCTION
The use of nonembryonic stem cells (SCs) has opened new avenues in developmental biology and regenerative 
medicine. Mesenchymal stromal/cells (MSCs)  constitute a heterogeneous population found first in bone marrow 
(BM) [2]. MSCs are easy to isolate [3], they have superior expansion potential as compared to other adult tissue-
derived SCs, and are endowed with low inherent immunogenicity and the ability to modulate or /suppress immuno-
logic responses [4].  These characteristics together with high plasticity,  a tendency to migrate into damaged tissues 
where they orchestrate regenerative processes, and their outstanding record of safety in clinical trials make these 
cells prime candidates for cellular therapy. Indeed MSCs from BM or umbilical cord blood have been used in 
therapeutic approaches involving haematopoietic, cardiovascular,  central nervous,  gastrointestinal, renal, and or-
thopedic systems, in experimental approaches to the treatment of genetic disorders and cancer [4, 5] as well as be-
ing considered for gene therapy [6, 7].
Adult BM is a common source of MSCs for clinical use [5], however the frequency of MSCs in human adult BM is 
relatively low, and availability  requires  invasive procedures. As a consequence a quest for alternative sources of 
MSCs was initiated, resulting in the identification of MSCs in multiple adult and neonatal tissues such as fat, skin, 
cartilage, skeletal muscle, synovium, peripheral blood, dental pulp, umbilical cord,  amniotic fluid and placenta [3, 
8-10]. While most of these are not practical sources of MSCs for use in routine clinical applications, the human 
placenta at term is an alternative, ethically acceptable, abundant and easily available source of MSCs. Fetal mem-
brane (FM) derived-MSCs are characterized by high plasticity [11-13], and are capable of differentiating into both 
their natural mesodermal and non mesodermal lineages [14-16], suggesting similar characteristics to BM-MSCs 
[17]. Amniotic membranes contribute to fetal maternal tolerance [18] and their allogenic transplantation, or trans-
plantation of cells derived from them, does not induce acute immune rejection even in the absence of immunosup-
pression [19-21]. It is not surprising therefore that FM-MSCs do not elicit allogeneic or xenogeneic immune re-
sponses, and are able to actively suppress lymphocyte proliferation [22-24].  In addition to the above mentioned 
therapeutic applications of MSCs, FM-MSCs are expected to be clinically used as autologous grafts for fetuses and 
newborns in peripartum tissue regeneration or for in utero transplantation in the case of genetic disorders without 
immunologic rejection by the recipient [25-27], proof of principle having already been established [28, 29]. Lastly, 
gene transfer in fetal blood derived MSCs with unperturbed differentiation potential has been performed [30],  thus 
confirming their potential use in gene therapy approaches, and large scale production and manufacturing for clini-
cal trials is being implemented [31-33].
Infections by herpesviruses are a common complication in organ transplants and during pregnancy. The human 
Herpesviridae family is composed of large, enveloped DNA viruses with close structural similarity and includes the 
Herpes simplex virus types 1 and 2 (HSV-1 and 2), Varicella zoster virus (VZV), Epstein Barr virus (EBV), Human 
Cytomegalovirus (HCMV), as well as Human Herpesvirus (HHV) types 6, 7 and 8. All members of the family rep-
licate in the nucleus of the infected cell after activating a coordinated cascade of mRNA synthesis,  that drives gene 
transcription in three temporal classes: immediate early (IE), early (E) and late (L). These viruses all share the abil-
ity to establish latency and reactivate at a later time [34]. Allogeneic SC transplantation is often complicated by 
reactivation of herpesviruses, which are also a cause of morbidity and mortality in patients undergoing  solid organ 
transplants [35].  The presence of selected viruses in MSCs from donor BM has been investigated [36],  human fetal 
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BM-MSCs support transcription of HHV-8 immediate early LANA messenger [39], while adult BM-MSCs have 
proved permissive to HSV-1 and HCMV [37, 38], raising concerns regarding their possible transmission to trans-
plant recipients. Furthermore several herpesviruses can establish congenital infections: structural fetal abnormali-
ties can result from intrauterine infection and transmission of the infection during pregnancy or at the time of deliv-
ery and can result in severe neonatal disease [40].
In the present study we aimed to investigate the susceptibility of FM-MSCs to all members of the human Herpes-
viridae family. As a whole, studying FM-MSCs permissivity to herpesviruses is relevant to: (i) the transplantation 
field, in that infection of plastic cells used in regenerative medicine pre or post transplant could interfere with their 
differentiation process and compromise the engraftment, inducing cytopathology or death of the implanted cells; 
(ii) vertical transmission of infections, a setting where the mechanism of virus spread through the placenta is vastly 
unexplored, and the consequences of congenital infection have been poorly characterized for most members of the 
family, especially in relation to stillbirth and post partum long term sequelae; (iii) gene therapy and viral vector 
mediated genetic modification of SCs. 
Our results clearly show that FM-MSCs are fully permissive to infection by HSV-1/2, VZV and HCMV. On the 
other hand, despite EBV, HHV-6, HHV-7 and HHV-8 being capable of entering FM-MSCs, only limited gene ex-
pression occurs, resulting in a nonproductive infection.
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MATERIALS AND METHODS
Antibodies. 
(i) Surface antigens analysis: mouse monoclonal antibodies anti-CD21 (clone LB21) and anti-CD35 (clone E11), 
were purchased from Antibodies-Online (Antibodies-Online INC., Atlanta, USA); anti-CD19 (clone HD37) ob-
tained from DAKO (DAKO, Glostrup, Denmark); anti-CD45 (clone 2D1, APC), CD11c (S-HCL-3, PE), CD14 
(MΦP9, PE), CD31 (WM-59,  PE), CD36 (NL07, FITC), CD90 (5E10, FITC), CD59 (P282-H19, PE), CD184 
(12G5, PE) and CD166 (3A6,  PE) were purchased form BD (Becton-Dickinson and Company, NewYork, USA); 
anti-CD106, (1G1b1-PE) were obtained from Southern Biotechnology (Southern Biotechnology Associates, Bir-
mingham, USA); HLA-DR (Tu36, FITC), CD 105 (SN6, PE), CD44 (MEM 85, FITC), HLA-ABC (Tu149, FITC), 
CD80 (MEM-233, PE), CD29 (MEM101A, PE) were purchased from Caltag Laboratories (Caltag Laboratories, 
Bangkok, Thailand), CD31 (CBL468F, FITC); CD34 (HPCA-2, Bdis, APC or PE-Cy7) were obtained from Cym-
bus Biotechnology (Cymbus Biotechnology, Chandlers Ford, UK).
(ii) Indirect ImmunoFluorescence (IIF): monoclonal mouse antibodies raised against HSV-1 and HSV-2 gD, 
clone HDI was a kind gift from Gabriella Campadelli-Fiume (University of Bologna, Bologna, Italy). HCMV anti-
IE clone E13 and anti-pp65, clone 1C3 were purchased from ARGENE SA (Varilhes, France). Anti-UL44 clone 
10D8 was obtained from Virusys (Virusys corp., Taneytown, USA). Fluorescin (clone sc2010) or Rodhamine 
(clone sc2092) conjugated secondary antibodies were purchased from Santa Cruz (Santa Cruz Biotechnology Inc., 
Santa Cruz, USA). All antibodies where diluted in PBS, according to the manufacturer’s instructions.
Cells. Human embryo lung derived fibroblasts (HEL) were cultured in minimal essential medium (MEM, PAA, 
Pasching, China), supplemented with 10% fetal calf serum (FCS) and 100 U/ml penicillin and 100 µg/ml strepto-
mycin (P/S). Human umbilical vascular endothelial cells (HUVECs),  were manteined in endothelial cell growth 
medium supplemented with 5% FCS and growth factors (EGM-MV single aliquots, both from BioWhittaker, Cam-
brex Bio Science, Walkersville, MD). Vero, and BHK cells were maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM, EuroClone, Milan, Italy) supplemented with 5% FCS, and P/S. Both T  lymphoid J-Jhan and Sup T1 
cell lines were grown in suspension in RPMI 1640 (EuroClone, Milan, Italy) supplemented with 10% FCS. 
FM-MSCs isolation, ex vivo culture and characterization. According to the policy approved by the local Ethical 
Committee (S.Orsola-Malpighi University Hospital, Bologna, Italy),  all tissue samples were obtained after in-
formed written consent. FM-MSCs were isolated as described previously [41]. Briefly, term placentas from healthy 
donor mothers undergoing caesarean sections were rapidly transferred to the laboratory, rinsed in Phosphate Buff-
ered Saline (PBS) containing penicillin and streptomycin (200 U/ml penicillin, 200 µg/ml streptomycin) and proc-
essed immediately. Pieces of fetal membrane were minced and subjected to 15-minute digestion with 0.25% 
trypsin-EDTA solution. The supernatant was discarded and the tissue underwent a second digestion with 0.25% 
trypsin-EDTA solution, 10 U/ml DNAseI and 0.1% collagenase IV solution in DMEM (all from Sigma-Aldrich, St. 
Louis, USA). Larger pieces of tissue were allowed to settle under gravity for 5 min at 37°C, while each supernatant 
was transferred to a fresh tube, neutralized with Fetal Bovine Serum (FBS, Biochrom, Berlin, Germany), then spun 
down at 400 g for 10 min. Each pellet was resuspended in 5 ml of DMEM containing 20% FBS, and P/S 100 µg/
ml.  Cells were seeded in 25 cm2 flasks and grown at 37°C in 5% CO2. Non-adherent cells were removed after one 
week and the medium (with 10 % of FBS) was subsequently changed every four days. When the culture reached 
90% confluence, cells were passaged using 0.25% Trypsin-EDTA. 
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Surface antigens were characterized as described elsewhere [41]. Briefly, trypsinized cells were resuspended in cell 
culture medium (10% FBS), incubated on ice for 10 min, washed with Dulbecco’s phosphate-buffered saline (PBS, 
pH 7.2, 10% FBS, Invitrogen, Carlsbad, USA), and labeled with 1 µg/106 cells FITC-conjugated antibodies for 40 
min at 4°C in the dark. 
Infection. Target cells were seeded either on 24- or 6-well culture plates at a cell density of 104 cells/cm2. When 
required, cells were layered onto coverslips in 24-well plates, grown until they reached approximately 80% conflu-
ence and infected as described below. 
Viruses. An HSV-1 clinical isolate at low passage from our diagnostic laboratory was used in most experiments. 
Alternatively, we used a fully replication competent derivative of the HSV-1 KOS strain, K26GFP, expressing 
VP26 as a fusion with the green fluorescent protein (GFP),  which leads to incorporation of GFP in the capsid [42], 
thus allowing easy direct identification of infected cells with an inverted fluorescence microscope. The low passage 
HSV-2 (G) laboratory strain was used in this study. Virus stocks were prepared and titrated in Vero (HSV-1 and 
K26GFP) and BHK (HSV-2) cells. Briefly,  supernatants (SNs) from infected cells approaching 100% cytopathic 
effect (cpe) were collected and subjected to three rounds of 20 sec sonication with a Bandelin Sonoplus sonicator, 
Model HD-2200 with an SH213G probe (Bandelin Electronic GmbH, Berlin, Germany) allowing a 1 min cooling-
off period between each sonication. Cellular debris were pelleted by centrifugation at 800 xg for 20 min at 4°C, and 
the SNs were aliquoted and stored at -70°C. Titration was performed by thawing frozen aliquots,  which were se-
quentially tenfold diluted and used in triplicate to infect Vero or BHK cells layered onto coverslips in 24-well plates 
for 1 h at 37°C, in a 5% CO2 atmosphere. The inoculum was then removed, cells were rinsed with 1 ml PBS and 
fed with fresh medium. 6 h post infection (p.i.) a neutralizing antibody was added to the medium in order to avoid 
extracellular spread of progeny virions. Plaques were counted three days post p.i. in wells where the dilution of the 
viral stock allowed less than 10 plaques to appear, and the correspondent titre was calculated. FM-MSCs were in-
fected with virus stocks at a multiplicity of infection (moi) varying from 1-2.5 plaque forming units (pfu)/cell. In-
fection was performed for 1 h at 37°C in a humidified CO2 incubator, then the inoculum was removed and fresh 
medium added. 
For VZV, a clinical isolate at low passage from our diagnostic laboratory was used in all experiments. Virus stocks 
were prepared in Vero cells by infection with cell-associated virus at a ratio 1:4, infected to uninfected cells in 75 
cm2 plastic flasks, harvesting infected cells when cpe was > 80 % with a cell scraper in their medium. Cell debris 
were subjected to three rounds of sonication as for HSV, except that cell debris were not separated from the me-
dium after sonication, but were directly aliquoted and stored at -70°C. Rough titrations were performed by infec-
tion of Vero cells with serial dilutions of the frozen stocks in 24-well plates, overlaying a 0.6% agarose containing 
culture medium 24 h p.i. and counting plaques at three days p.i. FM-MSCs were infected with VZV virus stocks at 
a multiplicity of infection (moi) < 1 pfu/cell. Infection was performed for 1 h at 37°C in a humidified CO2 incuba-
tor, then the inoculum was removed and fresh medium added.
As far as HCMV is concerned, we used the AD169 laboratory strain and the low passage endotheliotropic TB40 
strain. Viral stocks of TB40 were prepared in HUVECs, while AD169 was prepared in HEL. Viral stocks were ti-
trated in HEL as described elsewhere [43]. FM-MSCs and HEL were infected with HCMV viral stocks with an moi 
varying between 0.1 to 2.5 pfu/cell. Infection was performed for 1 h at 37°C in a humidified CO2 incubator, then 
the inoculum was removed and fresh medium added.
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HHV-6 viral stocks were obtained as previously described [44]; HHV-6 variant A (strain U1102) was grown in the 
T lymphoid J-Jhan cell line [45]; HHV-6 variant B (strain CV) was grown in the Sup T1 cell line [46]. A single 
inoculum was prepared and used for all infection experiments to avoid variability in the efficiency of infection due 
to differences in inocula. Briefly,  cell-free viral inocula were obtained by pelletting a total of 500 ml of cell cultures 
(at a concentration of 1 x 106 cells/ml) infected with HHV-6A or HHV-6B exhibiting complete cpe. The cells were 
lysed by 3 cycles of rapid freezing and thawing followed by sonication (3 cycles of 5 sec at medium power with 10 
second intervals in water bath sonicator). Cleared cellular content was added to culture supernatant and virions 
were collected by centrifugation at 20000 xg at 4°C. Virus particles were purified by density centrifugation using 
Optiprep self-forming gradients (Sentinel, Milan, Italy) at 5.8 x 104 xg for 3.5 h at 4°C. Collected virions were sus-
pended in PBS containing 1% bovine serum albumin, fractioned in aliquots of 100 µl and stored at -80°C until use. 
Prior to use, virus stocks were treated with DNase-I and RNase A, to eliminate free viral nucleic acids eventually 
present in the preparation. HHV-6 viral stocks were quantitated by real time PCR as already described [47] using 
primers which amplify both HHV-6 variants. The standard curve was generated by amplification of a plasmid con-
taining the targeted HHV6 sequences. The method had a 6-log dynamic range and a sensitivity of 20 copies/ml. 
FM-MSCs were infected with HHV-6A or B with a moi of 50 genomes/cell. Infection was performed for 2 h at 
37°C in a humidified CO2 incubator, then the inoculum was removed and fresh medium added. 
HHV7 Strain CZ [48] was grown in the Sup T1 cell line. Cell free viral inoculum was obtained as previously de-
scribed [46]. Briefly, 1 l of HHV-7 infected cell cultures exhibiting complete cpe was centrifuged at 900 xg, resus-
pended in 2 ml of FCS supplemented with RNase (50 µg/ml; Boehringer Ingelheim, Milan, Italy) and disrupted by 
four cycles of freezing in liquid nitrogen and thawing at 37°C. The resulting inoculum was completely free of liv-
ing cells,  as checked by microscopic observation and cultivation, and was also analyzed by reverse transcription 
PCR (both for β-actin and for a panel of viral mRNAs) to ensure that RNA was completely absent.  1x106 FM-
MSCs were infected with 400 µl of the resulting inoculum. Infection was performed for 2 h at 37°C in a humidified 
CO2 incubator, the inoculum was removed and fresh medium added.
The B95-8 cell line was used to generate infectious EBV virus. Cells were propagated in complete RPMI medium 
at 37°C and an atmosphere of 5% CO2, and fed 2 times per week, maintaining cell density between 0.5-1.0 x 106/
ml.  On day 0 12-O-tetradecanoylphorbol-13-acetate (TPA) was added to a final concentration of 25 ng/ml together 
with sodium butyrate to a final concentration of 4 mM. The cells were harvested on day 5. Cells that were not in-
duced were also harvested on the fifth day. Supernatant from both TPA induced and non induced B95-8 cell lines 
was used to infect FM-MSCs after clearance at low speed of cellular debris and subsequent filtration through a 0.8 
mm-pore filter to remove any remaining debris. Titration of inoculi was performed by determining the number of 
genomes present in serial dilutions of the final suspension with a real time PCR, targeting the exon 4/5 of the ter-
minal protein gene with primers EB-1 5’AACATTGGCAGCAGGTAAGC and EB-2 5’ACTTAC-
CAAGTGTCCATAGGAGC, and producing a 182 pb amplicon [49].
FM-MSCS infection was performed at 37°C in a humidified CO2 incubator for 2 h, then the inoculum was removed 
and replaced with fresh medium. Mock infections was performed with virus free medium in the same conditions. 
HEL cells were infected or mock infected in the same conditions in parallel.
When infected cells were cultured in 24 well chambers with coverslips at the bottom of each well, cells were ana-
lysed by IIF at 24, 48 and 72 h p.i., and every 3 days thereafter up to 21 days p.i.
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BC-3 cells, a KSHV/HHV-8 positive primary effusion lymphoma (PEL) – derived cell line, were used as a source 
of HHV-8 and virus was purified by a modification of the protocol described by Caselli and co-workers [50]. Cells 
were propagated in RPMI supplemented with 20% fetal bovine serum at 37°C and an atmosphere of 5% CO2, fed 
every 2-3 days for 3-4 weeks until a minimal amount of 2 x 108 cells was obtained. Cells were then treated with 
TPA at 20ng/ml (Sigma-Aldrich, St. Louis,  USA) for 60 h,  subsequently centrifuged and the supernatant was col-
lected. The cell pellet was lysed by three freeze-thaw cycles, centrifuged to eliminate cell debris, pooled with the 
supernatant, filtered through a 0.45-µm-pore-size filter, and concentrated at 4°C overnight with 7% polyethylene 
glycol 8000 (Sigma-Aldrich, St. Louis, USA). The suspension was centrifuged at 1.5 x 104 xg for 2 h at 4°C and 
the pellet was resuspended in a small amount of phosphate-buffer saline (PBS) and purified through a 25% sucrose 
cushion (2.65 x 104 xg for 3 h in a Beckman JSW-13-1 rotor). The pellet was resuspended in PBS and layered onto 
a 40-70% sucrose gradient and centrifuged at 2.65 x 104 xg for 1 h at 4°C in a Beckman JSW-13-1 rotor. The visi-
ble band was collected, dialyzed O/N against PBS, aliquoted and then stored at -80°C. Serial dilutions of this stock 
suspension were titrated by determining the number of genomes, with a real time PCR targeting the LANA gene, 
using primers HH8-1 5’TTGGGAAAGGATGGAAGACG and HH8-2 5’AGTCCCCAGGACCTTGGTTT, which 
determine an amplification product of 346 bp [51].
Nucleic Acid Purification. At specific time-points after infection cells were harvested by trypsinization, washed 
twice in cold sterile PBS, collected by centrifugation at 700 xg and stored at –80°C until processed. For nucleic 
acid extraction and purification cells were thawed, resuspended in 100µl of cold PBS and total nucleic acid were 
extracted with the NucliSENS easyMAG automatic extractor (bioMérieux sa, Marcy l'Etoile, France),  following 
the manufacturer’s instructions. Purified material was used both for DNA and RNA analysis.
Polymerase chain reaction (PCR) for detection of viral DNA in donor FM-MSCs. 2 multiplex PCR assays 
were performed, HERP-1 for HSV-1 and 2, VZV, EBV and HERP-2 for HCMV, HHV-6, HHV-7 and HHV-8. 
Primers included were previously described by others [49, 51, 52].
PCR analysis for detection of HHV-6A and B, and HHV-7 in infected FM-MSCs. To determine which samples 
harbored viral genomic DNA sequences, 1 µg of DNA (corresponding to 1.5 x 105 cells) was analyzed by nested 
PCR by using primers amplifying the U42 gene both for HHV-6A and B, and HHV-7. All primers were derived 
from the published HHV-6 and 7 sequences [53, 54]. The primer sequences as well as the PCR conditions were as 
previously described [45, 46, 55, 56].
Reverse Transcription-PCR (RT-PCR) for the detection of viral transcripts in infected FM-MSC. DNA en-
zymatic degradation was performed by means of DNAse I Amplification Grade (Invitrogen, Calrsbad, CA, USA). 
RT-PCR was performed with the SuperScript™ III CellsDirect cDNA Synthesis System (Invitrogen, Calrsbad, 
CA,USA), and specific sequences were PCR amplified in an automated thermal cycler, using the Perfect Taq Plus 
amplification kit (5 PRIME GmbH, Hamburg, Deutschland) according to manufacturer instructions. For detection 
of EBV, the three splicing form of the EBNA-1 transcript was amplified using the set of oligonucleotides previ-
ously published by Chen and co-workers [57], following their working conditions.  BZLF1 first round RT-PCR was 
performed using 1 µl of cDNA in a 50 µl reaction volume and 1.5 mM MgCl2 final concentration, using oligonu-
cleotides BZLF1-OUT-Fw 5’AGCAGACATTGGTGTTCCAC and BZLF1-OUT-Rv 5’ACATCTGCTTCAA-
CAGGAGG. Amplification reactions were carried out incubating samples at 95°C for 2 min then  a 35 round cycle 
constituting incubations at  95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec, followed by a final incubation at 
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72°C for 10 min. BZLF1 nested RT-PCR was performed with the same amplification conditions in combination 
with primers BZLF1-IN-Fw 5’ACGCACGGAAACCACAAC and BZLF1-IN-Rv 5’GCGCAGCCTGTCATTTT-
CAG. RT-PCR for the detection of HHV-6A and HHV-6B transcripts was performed as described elsewhere [45, 
58], while HHV-7 specific transcripts were analyzed as described in [46]. In the case of HHV8, ORF73 transcript 
was amplified using oligonucleotides ORF73-OUT-Fw 5’GAAGTGGATTACCCTGTTGTTAGC and ORF73-
OUT-Rv 5’AGTCCCCAGGACCTTGGTTT and 2.5µl of cDNA as template. ORF 73 semi-nested PCR was per-
formed using oligos ORF73-OUT-Fw and ORF73-IN-Rv. 5’TATCTCAGGCCTTCCAGTTT. ORF50 transcript 
was amplified with oligonucleotides ORF50-OUT-Fw 5’GCCCTCTGCCTTTTGGTT and ORF50-OUT-Rv 
5’GATGATGCTGACGGTGTG. Semi-nested PCR was performed with oligonucleotides ORF50-IN-Fw 5’ 
GCAAGGTCACTGGACTGTC and ORF50-OUT-Rv. All amplification reactions were carried out in a 50 µl reac-
tion volume, with 1.5 mM MgCl2 final concentration, using 2.5 µl of DNA as template. A common amplification 
protocol was used,  with the following conditions: 95°C for 2 min, 40 x (95°C for 30 sec, 60°C for 30 sec and 72°C 
for 60 sec), 72°C for 10 min final amplification.
Fluorescence Microscopy. Following fixation with paraformaldehyde 4% (w/v), cells were incubated with primary 
antibody for one h at 37°C in a humidified chamber. Three wash steps were subsequently performed in PBS, five 
min each at room temperature (RT). A secondary antibody, labeled with a fluorophore and raised against the species 
producing the primary antibody, was then incubated with the cells, in the same conditions as for the primary anti-
body. Antibody dilutions varied and were generally in compliance with manufacturers instructions. When human 
serum samples from our collection were used, dilution was generally 1:50. Cells expressing GFP-VP26 were incu-
bated with DAPI (1 µg/mL) for 4 min at RT to stain cell nuclei, after fixation with paraformaldehyde 4% (w/v). 
Samples were washed with PBS, mounted on coverslips in PBS/glycerol 50% (v/v), and imaged using a Nikon 
Eclipse E600 microscope equipped with a Nikon DXN1200 digital camera and a Nikon Plan Fluor 40x objective 
(Nikon, Tokyo, Japan). Live cells grown on Willcodishes (Willcowells, Amsterdam, The Netherlands) expressing 
GFP-VP26 fusion protein were imaged using a Nikon Eclipse E600 inverted microscope equipped with a Nikon 
DXN1200 digital camera and a Nikon Plan Fluor 40x objective (Nikon, Tokyo, Japan), as previously [42, 59, 60].
RESULTS
Herpesvirus genomes are not found in term placenta derived MSCs from healthy (seropositive) individuals 
FM-MSCs obtained from term placentas of 6 donors were analysed for the presence of herpesviruses genomes by 
means of 3 multiplex PCR assays developed in house, HERP-1 for HSV-1 and 2, and VZV, HERP-2 for HCMV, 
HHV-6, and HHV-7 and HERP-3 for EBV and HHV-8 [61]. No traces of any herpesvirus genome were found in 
any of the six populations of FM-MSCs used in this study (data not shown).
Permissivity of FM-MSCs to herpesviruses
To assess the infection efficiency of viral stocks, cell lines permissive  to HHVs infection were infected with the 
same moi used for  FM-MSCs and time-points were collected. 
All RNA samples were analysed by PCR without retrotranscription to check the total absence of DNA contamina-
tion. No contaminant DNA was present in any sample (see figures, RT-). Futhermore the efficiency of retrotran-
scription was monitored by amplification of the human β-actin cDNA, after a 1:100 dilution.
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Alpha herpesviruses
HSV-1 and HSV-2
MSCs originating from bone marrow have been shown to be permissive to HSV-1 [37], while heparan sulfate has 
been suggested as a major determinant for virus entry in adipose tissue derived MSC [63].  To investigate the degree 
of permissivity of FM-MSCs to HSV-1 and HSV-2, monolayers of FM-MSCs were infected with a clinical isolate 
of HSV-1, or the HSV-2 laboratory strain G. When infected cells were observed under an optical inverted micro-
cope, typical HSV-induced cpe became apparent from 16-24 h p.i at high moi (Fig. 1A), whereas cytopathic effects 
were observable only at later times after infection at low moi. Furthermore, IIF analysis allowed the specific detec-
tion of the L glycoprotein gD (Fig.  1B). Observation of cells infected at high moi from 18 h p.i. allowed the identi-
fication of polykaryons (Fig. 1B, bottom panels), whose formation requires L viral proteins gB, gD, gH and gL, 
that can be synthesised only after IE and E transcripts have been translated and DNA replication has been initiated. 
To verify that infectious progeny virus was released in the SN of infected cells, SNs were collected from infected 
cells at 2,  18 and 24 h p.i. and infectious virus was titrated on Vero or BHK cells in the case of HSV-1 or HSV-2, 
respectively. Our results show that infectious progeny virions arise from infected FM-MSCs, reaching titers of up 
to 107 p.f.u/ml (Fig. 1C). Interestingly, when FM-MSCs and control Vero cells were infected with the K26GFP re-
combinant HSV-1 virus, the VP26-GFP fusion protein was readily detectable in both cell lines, similarly accumu-
lating in the host cell nucleus by 20 h p.i.  (Supplementary Fig. 1). In conclusion, FM-MSCs can be regarded as 
fully permissive for both HSV-1 and HSV-2 viruses.
VZV
Viral genomic DNA has been PCR amplified from BM-MSCs isolated from two osteoarthritis patients in a sample 
of 18 patients [38]. However, susceptibility of MSC to VZV in vitro has never been addressed to date. We assayed 
the permissivity of FM-MSCs to VZV by infecting monolayers of FM-MSCs, or HEL as a positive control, with 
cell-associated VZV (moi < 1). When infected cells were observed under an inverted optical microscope, cyto-
pathic foci became clearly visible from 4 days p.i. both in HEL and in FM-MSCs (Fig. 2A, left panels). At 6 days 
p.i. signs of cell fusion, a hallmark of VZV infection started to appear (Fig. 2A, middle panels). The effect was 
more pronounced in FM-MSCs, where larger polykaryocytes were observable as compared to HEL. This was even 
more evident at 9 days p.i. when cytopathic effect was generalized in both cell populations. The presence of infec-
tious progeny virions was assayed on SNs from infected cells.  SNs were collected 6 days p.i. and processed for 
nucleic acid extraction and purification. PCR analysis was used to identify VZV genomic DNA in the extracted 
material. As shown in Fig. 2B, VZV specific amplicons were obtained from samples corresponding to SNs of in-
fected HEL and FM-MSCs. Our results clearly show that FM-MSCs are fully permissive to VZV.
Beta herpesviruses
HCMV
BM-MSC have been shown to be susceptibile to the AD169 strain [37] and to the clinical isolate TB40 [38] of 
HCMV. In a similar way we tested permissivity of FM-MSCs to both AD169 and TB40 viruses. To this end, we 
infected FM-MSCs, and HEL as positive controls, with both viruses at an moi of ≈ 1 pfu/cell.  At this moi,  a major-
ity of cells in an infected HEL monolayer will allow progression of the viral replication cycle; the percentage of 
cells hosting a full viral replication cycle in a cell population with unknown permissivity to HCMV compared to 
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that of a population of HEL infected in parallel with a comparable inoculum, reflects the permissivity of the cell 
type.  Cells were fixed at different time points thereafter. IIF assays were then performed with antisera directed to 
specific virus encoded products. In order to determine if representative members of all temporal classes of viral 
genes were expressed in these cells, we analysed the expression of IE, E,  and L genes at 24-96 h p.i. in both cell 
populations. As shown in Fig.  3A, viral encoded genes of all temporal classes of expression were expressed both in 
infected HEL and FM-MSCs. To analyze permissivity of FM-MSCs at the single cell level, counts were made of 
IIF positive cells for each antigen studied, at the indicated time points, and expressed as a percentage of the whole 
population. When the expression of the major IE gene UL123 was analysed upon infection with TB40 from 24 to 
96 h p.i. 82% of the cell population was found positive at 24 h, 90% at 48 h, 93% at 72 h and 95% at 96 h p.i. 
When the expression of the E gene ORFUL44 was analysed at 24 h and 48 h p.i., 58.5% and 72.6% of FM-MSCs 
stained positive respectively, while staining of the matrix protein expressed by the L gene ORFUL99 at 72 h and 96 
h p.i. resulted in 87% and 96% positivity.  When HEL cells were infected with TB40, or FM-MSCs and HEL were 
infected with a comparable inoculum of the AD169, we obtained similar results.  As a whole these data suggest that 
FM-MSCs are fully permissive to HCMV, and that a replication cycle takes between 72 and 96 h to complete when 
cells are infected at a moi of 1 pfu/cell.
To evaluate the kinetics of replication of HCMV in FM-MSCs at high moi as compared to HEL cells, and verify 
that infectious progeny virions are released by infected FM-MSCs, we infected both cell populations at a moi of 10 
pfu/cell with the TB40 strain.  At this moi, the viral replication cycle is syncronized in all cells of the monolayer, 
and in HEL cells at 72h pi progeny virions will appear in culture supernatants. The medium of infected cell mono-
layers was therefore collected after 3 days, centrifuged to eliminate cell debris and frozen, while cells were fed with 
fresh medium. SNs were then collected in the same way with a 3 day time interval until the monolayers were com-
pletely lysed by the virus.  A titration of all collected supernatants was then performed on HEL. As shown in Fig. 3B 
virus yield in both cell populations reached a peak at 6 days p.i. and decreased gradually.  HEL appeared more resis-
tant to the virus than FM-MSCs, the latter monolayer being completely lysed 2-3 days earlier. This accounts for a 2 
log lower virus yield at 18 days p.i. in FM-MSCs compared to HEL cultures. Taken together these results indicate 
that FM-MSCs are fully permissive to HCMV.
HHV-6
FM-MSCs were infected with a cell free inoculum of HHV-6A(U1102) or HHV-6B(CV). The inocula for the two 
viruses were standardized,  quantitating the viral genome by real-time PCR. Infection was performed using a moi of 
50 viral genomes/cell. The cultures were analysed at different times (1, 3,  7, 14, 21 and 28 days p.i.). Infected cul-
tures had a morphology similar to uninfected cultures and no cpe was detected (data not shown). DNA was ex-
tracted at all time points and anlyzed by single round PCR and nested PCR for the presence of HHV-6A and HHV-
6B DNA, with a PCR reaction specific for U42. For both variants, viral DNA was present at all time points, up to 
21 days p.i. after single step PCR, and up to 28 days p.i. by nested PCR (Fig. 4A). These results suggested that the 
amount of intracellular viral DNA decreased over time,  and therefore real-time quantitation of viral DNA was car-
ried out. The results of these experiments showed that the amount of intracellular HHV-6 DNA decreased from 
approximately 5 x 107 genome equivalents in 1.5 x 104 cells 24 h p.i. to 5 x 102 at 28 days p.i., and that both vari-
ants exhibited the same behaviour (Fig. 4B).  Therefore,  it is plausible to postulate that viral DNA persisted in in-
fected cells with low levels of viral replication. 
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To determine the replicative state of HHV-6 in infected FM-MSCs, viral transcription was analysed by RT-PCR for 
the presence of IE (U42) and L (U22) viral lytic transcripts. The analysis also included U94/rep, a latency-
associated transcript that is expressed at low levels during productive infection [45].  The sensitivity of PCR reac-
tions was similar for all genes, detecting 103 target molecules consistently after the first round of PCR and 10-50 
target molecules after nested PCR. Cells infected with HHV-6A showed the presence of U42 and U22 transcripts 
by first round PCR until 14 days p.i.,  and the transcript of U94 was detected till 21 days p.i. All three transcripts 
persisted as long as 28 days p.i., as shown by nested PCR (Fig. 4C). These results suggest that HHV-6A establishes 
a low level productive infection, characterized by scarce viral replication and decreasing amounts of viral products 
(both DNA and RNA) over time.
In the case of cells infected with HHV-6B, single round PCR failed to show the presence of viral transcripts, and 
nested PCR yielded positive results at all time points only for U42 and U94. The transcript of U22 was detected 
only during the first 3 days of infection (Fig. 4C). These results suggest that viral replication compatible with lytic 
production took place only for a few days, and that afterwards HHV-6B replication was restricted to the early phase 
of infection, with persistence of IE transcripts (U42 and U94), and the absence of late mRNAs (U22). 
Low grade HHV-6 infection and consequently low levels of viral replication may account for the lack of evident 
cytopathic effect in FM-MSC, which is clearly seen as large ballooning cells in primary human mononuclear cells 
or in selected T cell lines (JJhan).
HHV-7
FM-MSCs were infected with a cell free inoculum of HHV-7 strain CZ. The cultures were analysed at different 
times (1, 3, 7, 14, 21 and 28 days p.i.). Infected cultures had a morphology similar to uninfected cultures and no 
cytopathic effect was detected (data not shown). DNA was extracted at all time points and analysed by single round 
PCR, with primers and conditions specific for U42 of HHV-7. Viral DNA was detected at all time points, without 
the need for nested amplification (Fig. 5A). No precise quantitation was performed, however the low intensity of 
amplification bands at 21 and 28 days p.i. suggests that the amount of viral DNA decreased over time.  Analysis of 
viral transcripts was carried out by RT-PCR, in order to monitor expression of U42, U16/17 and U89/90 mRNAs. 
All these genes belong to the IE transcriptional class and are expressed at high levels throughout viral replication, 
starting immediately after infection [46]. Only U42 mRNA was detected at all time points, with a faint band after 
single step PCR. U16/17 and U89/90 mRNA were not detected,  even after nested PCR (Fig.  5B). On the whole, 
these results show that HHV-7 infects FM-MSCs cells, and that the virus persists without fully replicating , and 
expressing only some immediate-early functions [63].
Gamma herpesviruses
EBV
To assess the susceptibility of FM-MSCs to EBV infection, supernatant from a TPA induced B98-5 cell line was 
used to infect FM-MSCs and EBV susceptible HEK cells at a genome/cell ratio of 100. SN from non induced cells 
and serum free medium were used to establish mock infected controls.  The presence of the virus did not cause any 
morphological change either at the cell monolayer or at the single cell level as observed by light microscopy.
Amplification of DNA extracts from infected and mock infected cells and culture SNs from day 1 to 28 p.i. was 
performed, to investigate the presence of viral genomes in infected FM-MSCs. As shown in Fig. 6A genomic DNA 
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was amplified at up to 28 days p.i., with generally very weak signals. However, when the same samples were sub-
jected to a nested PCR analysis, specific DNA was amplified at all time points, suggesting that low levels of viral 
genomic DNA persists in the infected population. No DNA was amplified in any sample originating from infected 
or control cell SNs (data not shown). When virus specific transcripts were analysed in genomic extracts of infected 
cells by RT-PCR, as described in  materials and methods, no viral mRNAs were detected at any time point investi-
gated (Fig. 6B). Cytometric analysis of FM-MSCs revealed CD21 surface expression. These results taken together 
strongly suggest that EBV virions can enter FM-MSCs but transcription is not allowed while viral DNA persists for 
at least 4 weeks p.i. Since the cell monolayer is confluent by day 3/4 after infection, it is unlikely that failure to 
identify traces of viral transcripts or genome amplification is due to a dilution effect within a proliferating popula-
tion of cells. 
HHV-8
MSC from fetal BM can be infected latently in vitro by HHV-8, and virus persistence and expression of LANA/
ORF70 has been documented for over 9 weeks in those cells [39]. To assess the ability of HHV-8 to infect FM-
MSC, frozen stocks of purified virus were diluted in serum free medium and added to FM-MSCS at a moi of 50 
genomes/cell. Serum free medium was used to establish mock-infected controls. HUVEC cells were infected in 
parallel as positive controls. Infected cells remained unperturbed by the presence of the virus at all times p.i. as 
observed microscopically (data not shown). The presence of intracellular and extracellular viral DNA was assessed 
by PCR amplification of nucleic acid extracts obtained at days 1 to 28, from cell monolayer extracts and extracellu-
lar fluid. Qualitative and quantitative analyses were performed on both extracts as described in materials and meth-
ods. Viral DNA was readily detected at all time points tested (Fig. 7A). 
Analysis of virus encoded transcripts was performed on RNA extracted from mock infected and infected cells from 
1 to 28 days p.i., and analysed by RT-PCR. ORFUL50 and ORFUL73 mRNAs were retro-transcribed and resulting 
cDNAs were amplified with the specified primers as described in materials and methods.  As shown in Fig. 7B we 
did not detect any of the two transcripts at any time point analysed.  When the infection was performed at high moi 
(>103 genomes/cell) both ORFUL50 and ORFUL73 generated transcripts were detectable at 3 and 6 days p.i. (Fig. 
7C), but not at later time points (data not shown). Coexpression of a marker of latent infection (ORF73) and of the 
lytic-switch protein (ORF50) suggests a general,  albeit short lived activation of immediate early viral promoters, 
while the following cascade of genomic transcription would not be supported by the cellular transcription machin-
ery, nor would the transcriptional activity of ORF50 be allowed to proceed.
When quantitative analysis of virus genome copy number was implemented in high genome/cell ratio HHV-8 in-
fected FM-MSC, 1 genome per 25 cells was detected at 3 days p.i., 1 genome per 288 cells was found at 6 days p.i., 
while at 9 days p.i.  the amount of DNA was under the detection limit. Taken together these results suggest that 
HHV-8 is able to penetrate FM-MSCs and PCR detectable amounts of its genome persist for at least 4 weeks p.i., 
however limited gene expression is allowed only following high moi and for less than one week. 
Passage number and herpesvirus susceptibility 
We have tested the ability of FM-MSCs to sustain infection of the eight members of the human Herpesviridae fam-
ily starting at the 5th passage up to the 20th passage. No significant differences in infectability, virus yield, mRNA 
transcription or genome number and persistence were found in cells at the different expansion stages analysed, con-
firming the already described phenotypic stability of these cells throughout extensive expansion (data not shown).
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DISCUSSION
The present work addresses for the first time the susceptibility of FM-MSCs to all members of the Herpesviridae 
family. We show here that FM-MSCs are susceptible to HSV-1, HSV-2, VZV and HCMV infection in vitro. Sus-
ceptibilty remains unaltered from the 5th to the 20th passage. Our results show that HHV-6A persists in FM-MSCs 
cells with low levels of complete viral expression, and therefore with potential for production of infectious virus. 
On the other hand, HHV-6B and HHV-7 show a more restricted expression, with persistence of viral DNA and con-
tinuous transcription of some immediate-early genes. Even if late genes are not expressed, it is not possible to ex-
clude the possibility that these viruses might undergo full replication under specific conditions of the host cell. 
HHV-8 persists for at least 4 weeks in infected FM-MSCs, while specific transcripts are detectable only upon high 
moi,  but for not more than 6 days pi. Our data are consistent with the observation by Parsons and co-workers that 
expression of ORF73 is supported in fetal BM MSC upon infection at high genome/cell ratio [39]. In our experi-
mental settings duration of ORF73 transcription in infected cells was shorter, very likely due to lower doses of in-
oculi.
 
Ethical issues restrict the use of antenatal tissues as a source of SCs for scientific research and clinical applications. 
As an alternative one can rely upon the isolation of SCs from available fetal tissue samples, as with fetal bioptic or 
blood sampling and terminated pregnancies, or term placenta and postnatally retrieved FM, which yield mainly SCs 
with mesenchymal cell surface markers and morphology, MSCs. Amnion and chorion in particular constitute a 
valuable source of MSCs [11, 13, 14]. 
Herpesviruses are widely spread in the population, with seroprevalence rates ranging from a minimum of 30% for 
HCMV and 60% for HSV-1 in some Western developed countries, to over 90% for VZV, HHV-6 and 7 and EBV in 
the rest of the world  [64].
Our study, showing that FM-MSCs are fully permissive to members of the Herpesviridae family has implications 
in three medical research fields.  Firstly in regenerative medicine,  because herpesvirus infections remain a major 
challenge both in solid organ and hematopoietic stem cell transplantation,  two settings in which the use of FM-
MSCs is being implemented with growing expectation. Awareness of the possible contamination of isolated FM-
MSCs with viruses suggests the need to screen isolated cells for the presence of viral genomes, in order to avoid 
virus transmission to transplant recipients. Furthermore, the infection of transplanted tissues originating from the 
expansion of these cells could have adverse consequences on the outcome of the engraftment. Considerazioni su 
good manufacturing practices.
A second field of interest is that of vertical transmission of herpesviruses. Primary infection with HSV has been 
associated with spontaneous abortion, premature labor and intrauterine growth retardation, while primary VZV 
infection may result in stillbirth or cause congenital varicella, a syndrome associated with a significant mortality 
rate [65]. HCMV is the leading cause of congenital viral infection and the most common infectious agent of con-
genital malformations in developed countries. Viruses and other difficult to culture organisms have been postulated 
as the aetiology of a number of obstetric and paediatric conditions of unknown cause, including stillbirth.  Among 
herpesviruses, HCMV, HSV, and VZV may cause intrauterine deaths [66]. Infection of FM-MSCs with a member 
of the Herpesviridae family could have negative consequences on pregnancy and potentially the fetus at all times 
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of gestation. MSC from vascularized FMs could be a first target for replication and dissemination of virus to non 
vascularized FMs and to fetal circulation,  both serving as a reservoir of actively replicating virus, and interfering 
with the immune response of resident T  cells. Since FM-MSCs have been shown to enhance fetal repair [67] and 
couple immunesuppressant abilities to antimicrobial effector function [68], their depletion by viral infection could 
further complicate viral damage to the fetus. Furthermore herpesviruses are known to cause chromosome breaks in 
infected cells [69], that could represent a teratogenic threat to the fetus considering that MSCs traffic between pla-
centa membranes and the fetus [70], especially in very early developmental stages. Furthermore, since the placenta 
is not a barrier to maternal MSC trafficking, and BM derived MSC have been successfully infected in vitro with 
HSV-1 and HCMV, it is conceivable that vertical transmission could occur via this straightforward route.  The se-
verity of depletion or functional impairment of FM-MSCs during early gestation could depend upon maternal im-
mune competence towards HCMV which has been shown to occur for cytotrophoblasts [71]  and could disrupt pla-
centa implantation or cause abnormal placenta development, resulting in early failure. It is important to note here 
that our placenta-derived cells grow in cell culture conditions. The degree of their representativeness with respect 
to the original cell population constituting the stromal layer of mesenchymal tissue within fetal membranes has 
been considered with the intrinsic limitation due to an in vitro model. However, considering the high amount of 
MSC that can be isolated from a tiny area of fetal membranes, the number of passages needed to characterize the 
cell population is very limited (3-5), while our experiments were carried out at passage 6, when we would not ex-
pect major shifts in MSCs biochemical and biological characteristics would have occurred.
Finally our work is relevant to the field of virus mediated gene therapy applied to SCs. The importance of repro-
gramming FM-MSCs functions of interest or orienting their differentiation potential via gene transfer has been es-
tablished and has a broad consensus [72, 73]. 
Because of their propensity to migrate to sites of injury and their ability to expand rapidly,  FM-MSCs have been 
considered as potential gene transfer vehicles to deliver therapeutic genes [6, 7,  74]. On the other hand, gene trans-
fer to MSC is facilitated by using viral vectors [75-77]. Our results contribute to better predict how genetically 
modified versions of the different herpesviruses may be used to this end.  Using members of the Herpesviridae 
family for gene transfer can have several advantages: long-term transgene expression,  repeat vector dosing with 
minimal immune response due to the absence of helper viruses during viral packaging, and simultaneous delivery 
of large and multiple transgenes [78]. Hybrid HSV/EBV vectors have been used to enhance stability of transgene 
expression [79]. Their different behaviour in terms of genome stability and differential genome expression in in-
fected cells may be advantageous in distinct applications as diverse as transient expression for the induction of dif-
ferentiation or long term expression of therapeutic genes.
Considerazioni su good manifacturing practices e sicurezza negli impieghi clinici (Umbilical Cord Blood-Derived Mes-
enchymal Stem Cells Inhibit, But Adipose Tissue-Derived Mesenchymal Stem Cells Promote, Glioblastoma Multi-
forme Proliferation).
SUPPORTING INFORMATION
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Supplementary Fig. 1 Expression of a virus unrelated protein by a herpes simplex  based viral vector. Recom-
binant GFP  expressed by the replication defective vector TOZGFP-HSV1, carrying deletions in the immediate 
early genes ICP4, ICP22 and ICP27. GFP localizes in infected FM-MSCs and Vero with a comparable pattern.
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FIGURES AND LEGENDS
Figure 1. FM-MSCs are susceptible to HSV-1 and HSV-2 infection. (A) FM-MSCs were either mock infected 
(left panel) or infected with > 1 p.f.u/cell of the indicated viruses before being analyzed with an inverted optical 
microscope as described in the Materials and Methods section. The typical cytopathic effect shown is observed 
starting 12-18 h p.i; (B) FM-MSCs were either mock infected (top panels) or infected with > 1 p.f.u/cell of the in-
dicated viruses before being fixed and processed for IFF using a mAb directed against the late glycoprotein gD to 
detect infected cells, and DAPI to visualize cell nuclei. The bright field (BF) is shown in the left panels, and a 
merged image of all channels is shown in the right panels. Formation of typical syncithia in infected cells is evident 
starting at 18 h p.i., as shown in the HSV-2 bottom panels; (C) SNs of infected FM-MSCs were collected at the 
indicated times p.  i. and used to reinfect Vero (for HSV-1) or BHK (for HSV-2) cells to quantify infectious virion 
yields in the extracellular fluid of FM-MSCs by means of plaque assays as described in the  Materials and Methods 
section.
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Figure 2. FM-MSCs are fully permissive to VZV infection. (A) HEL or FM-MSCs were infected with VZV at a 
moi < 1 pfu/cell, as described in the Materials and Methods section. At the indicated time p.i. cells were analyzed 
by optical microscopy; (B) to determine if the observed cytopathic effect observed in (A) was indeed due to VZV 
infection,  VZV DNA was PCR amplified from extracellular fluid (including cellular debris): I.  DNA standard, II. 
Negative control (SN from mock-infected FM-MSCs), III.  Supernatant from VZV infected HEL, IV. Supernatant 
from VZV infected FM-MSCs, V. positive control (DNA extracted from VZV inoculi).
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Figure 3. FM-MSCs are fully permissive to HCMV infection. (A) FM-MSCs cells were infected with HCMV 
(srain TB40) at a moi of 1 pfu/cell and fixed at 24 (top panels), 48 (middle panels) or 96 (bottom panels) h post p.i. 
before being fixed and processed for IIF to stain HCMV temporal class representative antigens using IE (UL123), 
E (UL44) or L (UL99) specific antibodies, as indicated. The bright field (BF), the specific antibody signal (TRITC) 
and the cell nuclei (DAPI) are shown, with merged images presented in the right panels; (B) SNs from infected 
HEL cells or FM-MSCs were harvested at the indicated times p.i. and used to determine the titers of produced 
HCMV infectious virions by performing plaque assays on HEL cells as described in the Materials and Methods 
section.
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Figure 4.  FM-MSCs are susceptible to HHV-6 A/B variants. FM-MSCs were infected with HHV-6 (variant A 
and variant B) at a moi of 50 genomes/cell and nucleic acids extracted at the indicated times p.i.  As positive control 
an equivalent number of cells permissive to HHV-6 productive infection (J-Jhan for HHV-6A and SupT1 for HHV-
6B) were infected with the same viral stocks used for infecting the stem cells. A) single step PCR (1st) and nested 
(2nd) detection of HHV-6A and B genomes both in FM-MSC cells and J-Jhan and SupT1 cell lines. B) Real Time 
PCR quantification of HHV-6A and –B genomes. C) single step PCR (1st) and nested (2nd) RT-PCR for U42 (Early), 
U22 (Late) and U94 (latency associated) viral transcripts both in FM-MSC cells and J-Jhan and SupT1 cell lines. 
The β-actin retrotranscription-positive control is also shown.  C= mock infected FM-MSCs cells.  RT- = PCR ampli-
fication of RNA samples without retrotranscription.
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Figure 5. FM-MSCs are not permissive to HHV-7 infection. FM-MSCs were infected with HHV-7 and nucleic 
acids extracted at the indicated times p.i. As positive control an equivalent number of cells permissive to HHV-7 
productive infection (SupT1) were infected with the same viral stocks used for infecting the stem cells. A) HHV-7 
single step DNA PCR amplification both in FM-MSC cells and SupT1 cell lines. B) single step PCR (1st) and nested 
(2nd) detection of HHV-7 genomes both in FM-MSC cells and SupT1 cell lines.
The β-actin retrotranscription-positive control is also shown. C= mock infected FM-MSC cells. RT- = PCR amplifi-
cation of RNA samples without retrotranscription.
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Figure 6. FM-MSCs are not permissive to EBV productive infection.  (A) nested qualitative PCR performed on 
EBV infected FM-MSCs nucleic acid extracts: in the first amplification round viral DNA is amplified at all time 
points, although at barely non detectable levels. Second round amplification confirmed viral genomic persistence in 
infected cells; (B) nested RT-PCR against latency transcript EBNA-1 or lytic cycle associated BZLF1 transcript, on 
nucleic acids extracted from EBV-infected FM-MSCs failed to detect EBV transcriptional activity both in first and 
second round amplification (data not shown).
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Figure 7. FM-MSCs are not permissive to HHV-8 productive infection. (A) single step qualitative PCR per-
formed on nucleic acid extracts of FM-MSCs infected with HHV-8 at low moi (5 x 102 genomes/cell) detects a 
strong viral specific DNA signal at all time points tested. (B) nested RT-PCR against the latency transcript ORF73 
or the lytic cycle associated transcript ORF50, on nucleic acids extracted from HHV8 infected FM-MSCs at low 
moi (5 x 102 genomes/cell) failed to detect HHV-8 transcriptional activity both in first and second round amplifica-
tion (data not shown). (C) HHV-8 transcriptional activity is detectable by RT-PCR in high moi (5 x 103 genomes/
cell)  infected FM-MSCs: both ORF73 and ORF50 transcripts are amplified in single-step RT PCR until 6 days p.i
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Turning the HIV integrase into a dis-
integrase: tailoring a viral enzyme to pro-
mote the disruption of its natural target
Once  in  a target cell, the HIV RNA genome  is  reverse transcribed to DNA and then 
undergoes integration into the host genome that is  mediated by the  HIV integrase  (IN). 
IN is an  enzyme with no homologue in human cells and with  strong sequence specificity 
for HIV LTR ends. Current antiretroviral treatments do not eradicate the  infection 
from HIV reservoirs and are hampered by the appearance  of drug resistant strains. 
Here we present an attractive  alternative which could lead to the eradication of the 
HIV-1 provirus from infected cells: we have  conceived a novel fusion enzyme called 
trojIN in which IN is  covalently fused via a high flexible  fifteen-residue arm to the 
catalytic domain of FokI type II endonuclease (cdFok). In  our hypothesis trojIN chi-
meras specifically recognize  HIV-1 LTR DNA and excise it from insertion  sites via its 
non-specific DNA cleavage domain.
 Background. HIV-1 is  the etiological agent  of AIDS, a lifelong disease which if untreated leads to the 
death of the infected individual. In more than 30 years of research on the field of HIV-1, an impressive 
amount of progress has been achieved, and the production of new generation of anti-retroviral therapies 
has warranted a long life expectancy for infected people. However such therapies are not able to purge 
the organism from HIV-1 reservoirs, binding patients to a lifelong pharmacological treatment. The only 
way to free infected people from the HIV-1 plague is to clear viral reservoirs in the organism. This could 
theoretically be achieved in two ways: killing selectively all infected cells, or eradicating the provirus 
from sites of integration in their chromosomes. A way to selectively target  and eliminate latently infected 
T  cells is still unknown. In 1997 Batchu & Hinds proposed the substitution by homologue recombination 
of proviral DNA with an LTR-flanked therapeutic DNA, mediated by an IN-rep78 protein (1); however 
this fascinating hypothesis has never been translated into scientific publications. More recently Sarkar 
and coworkers have evolved Cre recombinase to recognize HIV-1 strain TZB0003 LTR. This modified 
recombinase recognizes specifically LTR and cleaves proviral DNA(2). Unfortunately, the LTR sequence 
of strain TZB0003 is atypical for HIV, and was chosen for these studies because of its similarity to the 
DNA sequence recognized by the wild type Cre recombinase. The corresponding LTR sequence from 
other HIV strains are much more divergent  from the wild type Cre recognition sequence, and thus it  is 
unlikely that  this approach can ever be generalized to clinically relevant HIV strains. Instead to evolve a 
DNA binding protein to viral specific sequences, Horner and DiMaio exploited the naturally occurring 
HPV E2 DNA-binding activity to assemble a chimeric nuclease: they generated a fusion protein between 
the E2 DNA binding domain and the FokI catalytic domain (cdFok). They tested the ability of such chi-
meric protein on HPV infected cells, and showed a predominantly specific DNA cleavage. Actually some 
off-target cleavage has been detected but  overall their results clearly show that  a naturally occurring viral 
DNA binding protein could be tailored as a weapon against  the virus itself (3). In our study we have se-
lected the HIV-1 IN as the naturally occurring viral DNA binding protein. IN is composed of three do-
mains: the N-terminal domain (aa 1-49), the catalytic core domain (aa 50-212), and the C-terminal do-
main (CTD; aa 213-288). The N-terminal domain has a His2-Cys2 zinc finger structure, similar to that 
commonly found in the DNA-binding regions of transcription factors and seems to be involved in the 
folding stabilization and proper multimerization of the integrase subunits (4, 5). The core domain plays a 
critical role in integrase enzymatic activity, includes the catalytic triad D64, D116, E152 and is involved 
in multimerization and in physical interaction with specific nucleotides inside LTR attachment sites
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(6,7,8,9). The CTD is involved in the binding with viral and cellular DNA and has frequently been asso-
ciated with unspecific DNA-binding activity (10). However several studies have shown that  specific 
CTD residues are involved in direct  interaction with specific LTR nucleotides. Over 60% of the IN ami-
noacidic sequence is highly conserved, and conserved residues are scattered over the entire sequence with 
clusters of conserved motifs, corresponding to functional sites, present  in all three IN domains. It is there-
fore hardly possible to introduce major modifications into the primary sequence of IN without  hampering 
its catalytic functions. However, when comparing IN sequence between different  animal retroviruses the 
less conserved domain is the CTD (11): we predict  that careful modifications altering the CTD of IN may 
leave its DNA specific recognition ability unaltered. Our first aim has therefore been to generate fusion 
proteins between native IN (and IN C-terminal mutants) and the catalytic core of FokI. We have created 
four different  trojIN versions: one carrying the native sequence of IN, trojIN, one based on a catalytic 
defective variant  of IN, trojIN D116A, in order to reduce possible catalytic interference by IN CCD to 
trojIN activity; in addition we have created two IN CTD-trojIN deletion mutants: one trojIN-delCTD in 
which all IN CTD coding sequence have been removed, and a trojIN version deprived of the last 18 IN 
aminoacid residues; the latter couple of mutants has been generated in order to remove or even attenuate 
IN non-specific DNA binding activity. Our final goal is the design of a novel enzyme that would act  as a 
trojan horse to the integrated HIV genome, retaining the ability to recognize the HIV LTR as its unique 
DNA binding target, but  once tethered to it would digest both DNA strands downstream to the binding 
site. We will test  trojIN activity in vitro on LTR bearing plasmids, in which U3 and U5 LTR attachment 
sites are juxtaposed or separated by several nucleotides in order to allow the head to head accommoda-
tion of two trojIN molecules, which would result  in pairing of the two cdFok on the opposing strands of 
interposed DNA (Fig. 1), and its subsequent cleavage.
Materials and Methods. 
E.coli  Strains and Construction of expression plasmids. Each construct was first propagated in E.coli 
strain TOP10. The names, sequences and main features of all oligonucleotides reported in this paper are 
listed in Table 1. Native  IN. Synthetic spacer L3 has been purchased from Integrated DNA Technologies 
(IDT) as single strand oligonucleotides; double strand spacer has then been obtained with a fill-in reac-
tion using the Rv L3 oligonucleotide as a primer for opposite strand synthesis. The PCR product was then 
cloned into the TA cloning vector pCR8 (Invitrogen) following manufacturer’s guidelines, which gener-
ated the pCR8-L3 construct. cdFok cDNA was PCR amplified from the Flavobacterium Okeanokoites 
(ATCC number 40898), with oligonucleotides Fw Fok and Rv Fok. The purified PCR product has been 
cloned into pCR8-L3 after appropriated RE digestion of both PCR product and acceptor plasmid, in order 
to obtain pCR8-L3cdFok. HIV IN cDNA has been PCR amplified from a clinical isolate of HIV infected 
cells with oligonucleotides Fw IN and Rv IN, while L3cdFok has been amplified with oligonucleotides 
Fw IN-Ln and Rv Fok. Both PCR products were then put together as primers/templates in an overlapping 
Fig. 1.  Schematic representation of  our experimental design. Each trojIN molecule bind to 
an LTR attachment site. The correct spacing between att sites will result in correct cdFok pair-
ment which in turn leads to DNA double strand break.
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PCR, which resulted in the assembly of trojIN cDNA. TrojIN cDNA has then been cloned into pUC19 
after RE digestion with the appropriated enzyme of both acceptor plasmid and PCR product, giving rise 
to pUC-TrojIN3 construct. TrojIN mutants. All trojIN deletion mutants (trojIN-del2, , trojIN-delCTD) 
have been generated following the aforementioned procedure with the exception of the oligonucleotide 
pairs adopted to amplify each IN mutant (see table1). Instead trojIN point  mutant trojIN-D116A a has 
been generated using the Quick Change Mutagenesis Kit (Agilent) following manufacturer’s instruction 
(see table 1 for oligonucleotides adopted for each mutagenesis). Gateway System. Both native and mu-
tated trojIN cDNA have been amplified with primers carrying attB1 and attB2 recombinant sites, using 
pUC-trojIN constructs as templates. Obtained PCR fragments have been inserted into the pDNR207 
plasmid (Invitrogen) via BP reactions, following manufacturer’s instructions. TrojIN cloned cDNA have 
been transferred to the gateway expression plasmids pDEST15 and pEPI-GFP, via LR recombination re-
action. The att0, att20 att40 targets where obtained by single strand synthesis using as template the pur-
chased positive strand and Rv LTR oligonucleotide as primer (table1). The PCR fragments were then gel 
purified and directly cloned into pCR8 as described above. The integrity of all constructs has been con-
firmed by DNA sequencing (PRIMM).
53
Fig. 2  Schematic representation of  DNA constructs used in this work.  A) TrojIN chimeras: 
cdFok domain (Blue) is linked by flexible L3 to the different IN subunits (Red, IN selected residues 
are between brackets). B) Target plasmid DNA: plasmid adopted in EMSA experiments: pCR8 is 
the negative control in which att0, att20, and att40 target sequences have been inserted. C) short 
sequences used in EMSA experiments.
A) B)
C)
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Oligonucleoti-
de 5'   -> 3' Sequence bases RE Site(s)
Spacer L3 CCGCGGGGAGGAGGAGGAAGCGGTGGAGGAGGCAGCGGCGGCGGTGGTAGCGCATGCTTTGGAGGTACC 69
SacII, SphI, 
KpnI
Rv L3 GGTACCTCCAAAGCATGCGCTACC 24 KpnI
Rv Fok GGGGGGTACCTTAAAAGTTTATCTCGCCGTTATTA 35 KpnI
Fw Fok GCCAGCATGCAAGCAACTAGTCAAAAGTGAACTGGAGGAGA 41 SphI
Fw IN-L3 CAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATCCGCGGGGAGGAGGAGGAAGCG 60
Fw IN GGTTTAGTCGACATTTTTAGATGGAATAGATAAGGCACAAGA 42 SalI
Rv IN CCGCGGATCCTCATCCTGTCTACTTGCCACACAATCATC 39
Rev Lat3 pUC GGAATTGGTACCTTAAAAGTTTATCTCGCCGTTATTAAATTTCCG 45 KpnI
Fw attB1 IN GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAACCATGGCGTCGACATTTTTAGATGGAATAGATAAGG 80
Rv attB2 Fok GGGGACCACTTTGTACAAGAAAGCTGGGTGGTACCAAAGTTTATCTCGCCGTTATTAAATTTC 63
F w d e l C T D -
Fok
GTAGACATAATAGCAACAGACATACAAACTAAAGAACCGCGGGG
AGGAGGAGGAAGC 57
Rv IN-NoCTD CTTTAGTTTGTATGTCTGTTGCTATTATGT 30
Fw del2-Fok CAAGAAGAAAAGCAAAGATCATTAGGGATCCGCGGGGAGGAGGAGGAAGCGGTGGAGGAG 60
Rv IN-del2 ATCCCTAATGATCTTTGCTTTTCTTCTTG 29
att0 GACCGGTTGTGGAAAATCTCTAGCAGTACTGGAAGGGCTAATTTACTGTCGACGTC 56 AgeI, SalI
att20 GACCGGTTGTGGAAAATCTCTAGCAGTGTAGTATATGCTTGTGTTCCACTGGAAGGGCTAATTTACTGTCGACGTC 76 AgeI, SalI
att40
GACCGGTTGTGGAAAATCTCTAGCAGTGTAGTATATGGTCATTCA
CAAGACTCTAGTCTTGTGTTCCACTGGAAGGGCTAATTTACTGTC
GACGTC
96 AgeI, SalI
RV LTR GACGTCGACAGTAAATTAGCCCTTCCAGT 29 SalI
Fw IN116A GCCAGTAAAAACAATACATACAGCAAATGGCAGCAATTTCACCAG 45
Rv IN116A CTGGTGAAATTGCTGCCATTTGCTGTATGTATTGTTTTTACTGGC 45
Prokaryotic protein expression and purification. GST-tagged or tag-less trojIN molecules were ex-
pressed in E.coli BL21 (DE3) (Invitrogen) strain under standard conditions: about  24h before induction a 
pre-culture of LB medium with trojIN expressing BL21 cells was set  up and grown at 37°C with constant 
swirling for 16-18h. After incubation an aliquot of growing culture was inoculated in fresh media at a 
ratio (v/v) of 1:50, and grown in the same conditions, until culture reached an OD of about 0,6-1,0. Then 
protein expression was induced by adding to the culture medium IPTG at  a final concentration of 0,5mM. 
Induced culture were harvested 6h post  induction by centrifugation at  200xg at  4°C for 30 minutes. Col-
lected cultures have been stored at -20°C until needed. GST tagged trojIN were purified by Glutatione-
Sepharose Beads (Amersharm) following producer’s suggestions. Tag-less trojIN proteins were purified 
from inclusion bodies essentially as reported previously (12): briefly harvested cells were resuspended in 
Tab. 1 DNA oligonuctleotides used in this work
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lysis buffer, subjected to mechanical and enzymatic lysis; then inclusion bodies were isolated by cen-
trifugation at 12000xg for 30 minutes, washed twice with a 4M Urea solution and then solubilized with a 
SDS based denaturing solution for 16h. The whole protein mixture has then been subjected to 8% SDS-
Page. The correctly sized protein was visualized in the acrylamide gel after CuCl2 negative staining, the 
corresponding gel band was excised and subjected to electroelution in SDS-running buffer. Purified tro-
jIN were refolded upon gradual removal of denaturing agents by step dialysis. The yield and integrity of 
purified proteins were assayed by SDS-PAGE followed by 1% Brilliant Blue Coomassie Staining or 
Western Blotting with mouse anti-IN monoclonal antibody (Santa Cruz). Purified proteins were stored in 
50% glycerol buffer at -20°C.
EMSA. Purified trojIN variants activity and correct  folding has been tested in DNA binding assay: 
3,5pmol of trojIN were incubated with either 0.05pmol of plasmid DNA or 1,5pmol of 100bp long 
dsDNA for 1h at  37°C or 24h in different Tris-based buffers. Plasmids/trojIN macromolecular complexes 
were resolved by 0,8% agarose gel electrophoresis run1h at  100V in 0,5x TAE buffer (Tris 20mM, Acetic 
Acid 10mM, EDTA-Na2 0,5mM). Short  DNA/trojIN complex were resolved in 8% acrylamide gels run at 
100V for 1h in TBE buffer (Tris 45mM, Boric Acid 88mM, EDTA-Na2 0,2mM).
Results. 
Fig. 3 TrojIN solubility evaluation. Western Blot Analysis of differentially induced trojIN 
expression, in order to obtain native soluble chimeric protein. MwM, Molecular Weight 
marker; Lanes 1, 2 trojIN expression was induced for 5h at 37°C; Lanes 3,4 trojIN induction 
have been carried out at 4°C for 72h; 5, 6 trojIN expression induced for 16h at 20°C. Lanes 
1, 3, 5 Native soluble fractions; Lanes 2, 4, 6 total lysate
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WB and purification. We have overexpressed several trojIN variants (summarized in fig. 2A) in E.coli 
BL21 strain, a suitable strain for protein overexpression, in which the main prokaryotic proteases has 
been genetically shut down. The expression was induced by adding IPTG and by incubating culture at 
different  times and temperatures. We first expressed trojIN tag-less, in order to avoid fusion partner inter-
ference to trojIN activity. We have assayed different inducing conditions in order to improve trojIN solu-
bility but  first attempts to obtain tag-less soluble trojIN molecules in detectable amounts by Coomassie 
staining or WB analysis failed (Fig. 3). Next  we assayed the solubility of GST-tagged trojIN molecules, a 
fusion partner largely used to enhance solubility and purification yield of overexpressed proteins (13). As 
shown in figure 4 GST fusions led to an increased solubilization of trojIN: chimera soluble fractions were 
more than barely detectable (figure 4A, LANE SN1); furthermore an abundant  amount of fusion protein 
became soluble after treatment with a low concentration Urea buffer (see fig. 4A LANE SN2) suggesting 
that GST fusion allowed formation of almost soluble trojIN. We have proceeded further purifying GST-
tagged trojIN as described in material and methods section. WB analysis of purification steps showed 
only a faint  band in the “Eluate3” lane, at  the expected molecular weight  (figure 4B, lane E3); moreover 
all three elution steps showed marked degradation products. Furthermore a visible signal was detectable 
in the fraction corresponding to unbound fraction. These results were suggestive of a not properly cor-
rected folding of GST-trojIN in the case of unbound fraction, and of an overall instability of the fusion 
products, highlighted by a high level of degradation, even in the presence of protease inhibitors. Parallel 
purification with another GST-fusion protein (HCMV UL54) has strengthened our conclusion: in fact 
induction and purification in the same conditions led to an appreciable amount  of purified control protein 
(data not shown). In order to obtain high level of stable purified protein we next  have extracted tag-less 
trojIN from inclusion bodies: correct  sized trojIN were then isolated from denaturing PAGE and refolded 
under native conditions. As shown in figure 3 the above purification strategy has allowed us to obtain 
high level, high pure tag-less trojIN molecules.
Figure 4. GST-trojIN expression and purification. A) GST-trojIN chimera expressed in BL21 cells was 
partially extracted from cells with a native lysis buffer and trojIN expression was detected with anti IN 
antibody: Lane 1 Un-induced BL21, total lysate; BL21 total lysate after 5h induction at 37°C;  Lane 3 
soluble fraction after non denaturing cell lysis; Lane 4 soluble fraction after 4M urea wash of insoluble 
material. B) Soluble GST-trojIN protein have been subjected to purification on Glutathione-Sepharose 
Beads colums and obtained fractions were analyzed with Western Blot developed with anti IN antibody: 
Lane 1 Lysate soluble fraction; Lane 2 Column flow trough (unbounded fraction); Lane 3 and 4 low Glu-
tathione concentration eluted fraction. Lane 5 Eluted Fraction.
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EMSA (1) plasmid. Since it has been previously shown that  HIV-1 IN is able to bind LTR-carrying 
plasmids (14), we have assayed the ability of each trojIN version to bind linearized plasmid DNA carry-
ing or not  HIV-1 LTR attachment  sites (see target  section fig. 2), by EMSA on agarose gels. Besides in-
cubation with LTR bearing DNA and functional trojIN molecules could result in some kind of cleavage 
of target DNA molecule. First we assayed the ability of all trojIN variants to bind to specific (with LTR) 
or non-specific plasmid (fig 4A-B): while native trojIN, the point  mutant D116A and the negative control 
(protein storage buffer) seemed not to influence DNA electrophoretic mobility, trojIN deletion variants 
(trojIN-del2, trojIN-delCTD) appeared to bind both LTR carrying or negative control plasmids, slowing 
down their migration speed. Anyway under no circumstances trojIN-DNA incubation resulted in detect-
able cleavage of a DNA fragment. Next we have tried to optimize buffer composition with the trojIN ver-
sion del2 in order to devise optimal conditions for LTR-specific binding: as shown in figure 4C, trojIN-
del2 confers mobility shifts to LTR bearing plasmids but  not to control DNA in buffer NEB2. We then 
have performed EMSA assays varying the incubation times up to 24h), but  failed to detect DNA diges-
tion products (data not shown). All above described EMSA assays have been carried out in the presence 
of high zinc ion concentration (50µM); it is well known that  free zinc is required for proper IN 
dimerization/multimerization and to enhance Mg2+ dependent  IN activity (15,16,5) . In order to evaluate if 
the observed DNA binding was correlated to IN multimerization, we have performed EMSA assays with 
varying Zn2+ concentrations: as illustrated in figure 4D trojIN retained its ability to bind DNA in standard 
Zn2+ concentration as seen in previous experiments. In contrast EMSA performed in reaction buffer with a 
5 fold reduction in zinc concentration or without Zn2+ ions, showed abolished trojIN induced mobility 
shift.
Fig. 5 Tag-less trojIN purification from inclusion bodies. BL21 expressing 
Tag-less trojIN were lysed as described in material and methods section. Purifica-
tion steps where resolved on 8% SDS-PAGE and detected with Coomassie Bril-
liant Blu staining: Lane 1 Inclusion bodies total extract; Lane 2 trojIN inclusion 
bodies after UREA wash and 1% SDS denaturation;
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Fig 6.  Agarose EMSA with trojIN variants,  trojIN 
specific DNA binding has been evaluated under dif-
ferent saline conditions.
A) Lanes 1, 4 pCR8 plasmid; Lanes 2, 5 att0 plas-
mid; Lanes 3, 6 att40 plasmid. trojIN-del2 (lanes 
1-3) incubated with specific or aspecific DNA 
target in buffer 2 (TrisHCl 10mM pH 7.9, NaCl 
50mM, MgCl2 10mM, DTT 1mM) was run on 
0,8% agarose gel.  In lanes 4-6 samples are Dialy-
sis bufferer incubated with DNA targets as nega-
tive controls.
B) trojIN WT (lanes 1-3), -delCTD (lanes 4-5) and 
-D116A (lanes 7-9)  trojIn variants or dialysis 
buffer (lane 10) incubated with pCR8 (Lanes 1, 
4, 7, 8) att0 (Lanes 2, 5, 8) or att40 (Lanes 3, 6, 9) 
were run on 0,8% agarose gel.
C) trojIN-del2 variant was incubated with att20 or 
control plasmids in different saline buffer condi-
tions. Lanes 1, 5 Buffer 1 (Bis-tris-propane HCl 
10mM pH 7.0, MgCl2 10mM, DTT 1mM); Lanes 
2, 6 Buffer 2; Lanes 3, 7 Buffer 3 (TrisHcl 50mM 
pH7.9, NaCl 100mM, MgCl2 10mM, DTT1mM); 
Lanes 4, 8 Buffer 4 (TrisAcetate 33mM pH 7.9, 
K-Acetate 66mM, Mg-Acetate, DTT 1mM). As 
control Dialysis buffer (H2O) was incubated in 
teh same conditions (Lane 9 Buffer 1, 10 Buffer2, 
11 buffer3) 
D) EMSA after trojIN-del2 interaction with att20 
plasmid in buffer 2 with different free zinc con-
centrations 
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EMSA (2) short DNA. EMSA has also been assayed with low molecular DNA target carrying LTR at-
tachment sites, called att40 from now on, or with a same length control DNA; we have adopted the same 
optimized conditions determined above. Figure 5B shows clearly that IN binds both to specific or non-
specific DNA: electrophoretic mobility of trojIN-del2 protein, incubated in reaction buffer in the absence 
of DNA (lane5) is higher if compared with DNA associated trojIN-del2 complex (lanes 1-4 and 6-9). It 
appears unequivocal that  DNA-trojIN interaction resulted in a high molecular weight complex formation. 
Furthermore as observable in fig 5a-lane 4, trojIN-del2 protein reduced DNA electrophoretic mobility in 
a LTR specific fashion since a shift  in control-DNA electrophoretic mobility was not  detected (compare 
lane 4, att40 with lane9, control DNA). However DNA/trojIN complex formation seem less efficient on 
short  DNA substrates compared with plasmid DNA: only the addition of high amount of DNA substrate 
(1,5pmol, fig.5A lane 4) allowed trojIN-del2 to impose mobility shift as observable comparing lane 4 
with lanes 1 to 3 (Fig. 5a). This results suggests that on short DNA an high trojIN:DNA ratio could in-
hibit complex formation. Anyway at  any rate trojIN incubation with short DNAs resulted in DNA diges-
tion.
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Fig. 7 EMSA after trojIN-del2 incubation with 
att40 or control Short DNAs.
A) Etidium bromide staining of TBE-PAGE 8%. 
TrojIN-del2  (Lanes 1-9) incubated with 
buffer2 (lane 5) or with different amount of 
att40 DNA(Lanes 1-4) or control DNA (Lanes 
6-9). Lanes 1, 6 0,15 pmol of DNA;  Lanes 2, 7 
0,38pmol of DNA; Lanes 3,8 0,75pmol of 
DNA; Lanes 4, 9 1,5pmol of DNA. Lane 10 
att40, Lane 11 Control DNA. 
B) Migrated DNA/protein complexes were trans-
ferred on Nitrocellulose subsequently subjected to 
Western Blot analysis with anti IN antibody
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Discussion and future perspectives. 
HIV establishes lifelong latency within infected memory T  cells, and current therapies cannot eradicate 
the infection, even if they successfully inhibit viral replication. The only definitive cure for the HIV in-
fection lies in the complete elimination of latently infected cells or of the integrated provirus they carry. 
Recent works have attempted to remove the T  cell compartment by non-specifically activating HIV 
within memory T  cells, hoping that  activated viral replication would result in the disruption of latently 
infected cells (17,18). But  such promising approaches have to date proven unsuccessful. Furthermore it  is 
hard to predict  the effects of a widespread T-cell disruption consequent to targeting HIV latently infected 
T  cells for destruction, on the ability of the infected individual to reconstitute an effective immune re-
sponse. Alternatively an attractive approach would be to selectively target the integrated provirus within 
these cells. Our work belongs to this novel field of research, a preliminary and rather incomplete attempt 
to generate a molecular tool for the excision of the HIV provirus from insertion sites: we have generated 
four different  trojIN candidate enzymes, namely trojIN, trojIN-D116A, -del2 and –delCTD. We have 
tested the ability of these novel chimeras to bind LTR bearing DNA. As a result  we have identified two 
trojIN variants –del2 and -delCTD, which bind electively (-del2) or with more efficiency (-delCTD) the 
LTR bearing pCR8-att20 plasmid. In addition trojIN-del2 apparent  preference for LTR bearing DNA has 
been confirmed by EMSA experiment performed with the 100bp-long LTR carrying att40 DNA 
(Fig5a,b): trojIN–del2/att40 interaction with a 1:2 molar ratio resulted in a lowered DNA electrophoretic 
mobility, which is not detectable in the case of trojIN-del2/control DNA interaction. These results are 
consistent with our working hypothesis, namely that  suitable modifications of the CTD sequence may 
reduce IN binding to non-specific DNA. However the reason for full-length trojIN inability to bind DNA 
in our hands remains elusive, since IN protein is able to bind plasmid DNA in vitro(14). One possible 
explanation could reside in the presence of cdFok which could interfere with the correct  folding of full 
length IN. Anyway the main result  is at any rate the lack of a detectable cdFok activity,  and it  is possible 
that DNA cleavage products are not  detected in our experimental conditions due to very low efficiency of 
the reaction. Another explanation could be an inappropriate trojIN complex formation: the rationale be-
hind target  design was to mimic naturally occurring 2LTR circles, an  hypothesized viral DNA reservoir 
in infected cells (19), which has been demonstrated to be recognized in in vitro experiments by recombi-
nant  IN. We have introduced spacer nucleotides between LTR att sites in order to allow proper distancing 
between LTR- bounded trojIN molecules: it  is well known that  cdFok cleaves DNA upon dimerization 
with a partner cdFok domain (20) and a correct trojIN distancing would allow proper cdFok dimerization 
which in turn would result in DNA cleavage (Fig. 8A). On the contrary if spacing between trojIN mole-
cules would not  be correct, namely LTR att sites are too far or contiguous cdFok subunit  couldn’t  interact 
suitably, resulting in lack of cleavage activity (Fig. 8B). Moreover trojIN dimerization could occur be-
tween IN surfaces (Fig. 8C/D), resulting in a constrained trojIN dimer, potentially unable to be catalyti-
cally active.
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The actual trojIN dimerization, if occurring, would not be easily predictable, but we can try to minimize 
un-functional trojIN dimer formation: it  has previously characterized by others (21) a IN single-
aminoacid mutant  with impaired IN omo-dimerization; adopting a trojIN version carrying such mutation 
we could reduce trojIN un-functional dimerization. However at the moment  we are working into two 
main directions in order to obtain more functional chimeras: one is the creation of trojIN variants with a 
lengthened flexible arm connecting IN and cdFok, which could  overcome eventually occurring struc-
tural constrain between the two trojIN domains. Another possibility to enhance trojIN specific activity is 
to set up an in vivo evolution system: we are now working on an adapted in vivo evolution system per-
formed in prokaryotic cells and inspired by the work of Barbas III's group (22): briefly we have inserted 
our targets DNA (att0, att20, and att40) into a toxic gene (ccdB) expressing plasmid, and with them trans-
formed BW25141 strain, an engineered E.coli strain capable of a rapid degradation of linear DNA (23). 
The induction of ccdB gene expression leads cells to death, warranting a stringent selection system. Sub-
sequently we have created a cDNA library with randomly mutated trojIN, which have been subjected to 
recombination via DNA shuffling and subsequent cloned into an expression plasmid. TrojIN plasmid 
have been used to transform the BW25141 strain of E. coli, carrying the LTR-ccdB plasmid, and the ex-
pression of both toxic gene and trojIN have been induced: only clones transformed with trojIN having 
some degree of activity have grown, representing the first  generation of selection. DNA plasmid ex-
tracted from selected colonies have then be used as templates to amplify trojIN with error-Prone PCR, 
creating a new library of mutated chimeras. Finally we have repeated recombination and in vivo selection 
obtaining trojIN second generation. Preliminary results are promising: in the first  generation we have 
obtained about  ten colonies, while in the second about  two times suggesting an increased trojIN effi-
ciency. Furthermore the  preference for att20 target  plasmid observed in EMSA experiments (Fig.4) seem 
to occur even in the selection system,  supporting our in vitro results. Functional trojIN variants will be 
transferred in eukaryotic reporter system: we plan to create a fluorescent  reporter cell line transduced 
with a GFP expressing lentiviral vector. TrojIN activity will be measured after transfection of the reporter 
cell line with an eukaryotic trojIN expression vector: cytofluorimetric analysis over time of the number 
of GFP  expressing cells will be the measure of trojIN specific activity. Furthermore cytofluorimeter will 
allow us to determine the cell cycle phase of analyzed samples: for example a cell population with re-
duced amount of population and in a SubG0 phase will be suggestive of apoptotic events, probably due to 
trojIN cytotoxic activity or trojIN off-target activity. The resulting positively selected trojIN variants will 
be bona fide candidate for moving toward pre-clinical research phase.
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Fig. 8  Schematic representation of hypnotized trojIN molecular rearrangement on target DNA.
A) Correctly spaced  trojIN pair allow proper cdFok dimerization and subsequent DNA cleavage, 
which couldn't take place if LTR sequences are too far from each other (B). C) Also dimeriza-
tion trough IN interface could lead the proper pairing of two cdFok domains, but could  also 
result in physical separation of the two cdFok domains (D).
D)C)
B)A)
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